|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [MAP3K1 protein results in increased expression of ABCB1 mRNA]; pyrazolanthrone inhibits the reaction [Oxygen deficiency results in increased expression of ABCB1 mRNA] pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of and results in increased activity of ABCB1 protein]; pyrazolanthrone inhibits the reaction [Vehicle Emissions results in increased expression of and results in increased activity of ABCB1 protein] |
CTD |
PMID:15604272 PMID:18474546 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]]; pyrazolanthrone inhibits the reaction [2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]]; pyrazolanthrone inhibits the reaction [7-Ala-angiotensin (1-7) inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]]; pyrazolanthrone inhibits the reaction [7-Ala-angiotensin (1-7) inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]] |
CTD |
PMID:27302421 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Streptozocin results in increased activity of ACHE protein] |
CTD |
PMID:20600246 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
crocin promotes the reaction [pyrazolanthrone inhibits the reaction [TNFSF11 protein results in increased activity of ACP5 protein]]; pyrazolanthrone inhibits the reaction [TNFSF11 protein results in increased activity of ACP5 protein] |
CTD |
PMID:30580027 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride promotes the reaction [pyrazolanthrone inhibits the reaction [Folic Acid results in increased expression of ACTA2 protein]]; pyrazolanthrone inhibits the reaction [Folic Acid results in increased expression of ACTA2 protein]; pyrazolanthrone promotes the reaction [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride inhibits the reaction [Folic Acid results in increased expression of ACTA2 protein]] |
CTD |
PMID:31447676 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [hydroquinone results in increased expression of ADAM17 protein]; pyrazolanthrone inhibits the reaction [hydroquinone results in increased expression of and results in increased stability of ADAM17 mRNA] |
CTD |
PMID:23791922 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [TNF protein results in decreased expression of ADIPOQ mRNA] |
CTD |
PMID:18577375 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of AGER protein] |
CTD |
PMID:33075463 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of AGTR1 mRNA] |
CTD |
PMID:23603059 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
pyrazolanthrone binds to and results in increased activity of AHR protein |
CTD |
PMID:17959153 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [arsenic trioxide affects the localization of AIFM1 protein] pyrazolanthrone inhibits the reaction [Acetaminophen affects the localization of AIFM1 protein] pyrazolanthrone inhibits the reaction [cadmium acetate affects the localization of AIFM1 protein]; pyrazolanthrone inhibits the reaction [Isoflurane results in increased cleavage of and affects the localization of AIFM1 protein] |
CTD |
PMID:18412143 PMID:20423716 PMID:24577723 PMID:25043952 PMID:29289695 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Curcumin results in increased expression of AKR1B1 mRNA] |
CTD |
PMID:17640564 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases expression |
ISO EXP |
pyrazolanthrone inhibits the reaction [arsenic trichloride results in increased activity of AKT1 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in decreased phosphorylation of and results in decreased activity of AKT1 protein]; pyrazolanthrone inhibits the reaction [cholix toxin, Vibrio cholerae results in increased phosphorylation of AKT1 protein]; pyrazolanthrone inhibits the reaction [diallyl trisulfide results in decreased phosphorylation of AKT1 protein]; pyrazolanthrone inhibits the reaction [Fingolimod Hydrochloride results in decreased phosphorylation of AKT1 protein]; pyrazolanthrone inhibits the reaction [Indomethacin results in increased phosphorylation of AKT1 protein]; pyrazolanthrone inhibits the reaction [rhoifolin results in decreased phosphorylation of AKT1 protein] pyrazolanthrone results in decreased expression of AKT1 protein pyrazolanthrone inhibits the reaction [etoxazole results in increased phosphorylation of AKT1 protein]; pyrazolanthrone inhibits the reaction [flufenoxuron results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:16046226 PMID:17341418 PMID:20534739 PMID:22020565 PMID:22696236 PMID:25939952 PMID:28087840 PMID:33618463 PMID:33771252 PMID:35383226 More...
|
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
ISO |
[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of AKT2 mRNA; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of AKT2 mRNA] |
CTD |
PMID:30580027 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
decreases expression |
ISO |
pyrazolanthrone results in decreased expression of ALOX5 protein |
CTD |
PMID:23539630 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Ampd3 |
adenosine monophosphate deaminase 3 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Ozone results in increased expression of AMPD3 mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Phosphatidylinositols results in increased expression of APOA1 protein] |
CTD |
PMID:19013290 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apod |
apolipoprotein D |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of APOD mRNA]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of APOD protein] |
CTD |
PMID:21688324 |
|
NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [[Clioquinol co-treated with Copper] results in decreased expression of APP protein alternative form]; pyrazolanthrone inhibits the reaction [APP protein results in increased expression of and results in increased cleavage of CASP1 protein]; pyrazolanthrone inhibits the reaction [APP protein results in increased expression of and results in increased cleavage of IL1B protein]; pyrazolanthrone inhibits the reaction [APP protein results in increased expression of NLRP3 protein] |
CTD |
PMID:16648635 PMID:28004443 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp1 |
aquaporin 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AQP1 protein] |
CTD |
PMID:21647617 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
pyrazolanthrone affects the reaction [Quercetin inhibits the reaction [mibolerone results in increased expression of AR protein]] |
CTD |
PMID:20148354 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Atf2 |
activating transcription factor 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased phosphorylation of ATF2 protein]; pyrazolanthrone inhibits the reaction [2-aminodiphenyl results in increased expression of and results in increased phosphorylation of ATF2 protein]; pyrazolanthrone inhibits the reaction [ATF2 protein results in decreased susceptibility to Cisplatin]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of ATF2 protein]; pyrazolanthrone inhibits the reaction [Cisplatin results in increased activity of ATF2 protein]; pyrazolanthrone inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of ATF2 protein]; pyrazolanthrone inhibits the reaction [hydroquinone results in increased phosphorylation of ATF2 protein]; pyrazolanthrone inhibits the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate results in increased phosphorylation of ATF2 protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of ATF2 mRNA]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of ATF2 protein modified form]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of ATF2 protein]; pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of ATF2 protein] pyrazolanthrone inhibits the reaction [[[cupric chloride results in increased abundance of Copper] co-treated with [zinc chloride results in increased abundance of Zinc]] results in increased phosphorylation of ATF2 protein]; pyrazolanthrone inhibits the reaction [Anisomycin results in increased phosphorylation of ATF2 protein]; pyrazolanthrone inhibits the reaction [trovafloxacin results in increased phosphorylation of ATF2 protein] |
CTD |
PMID:12393500 PMID:12663670 PMID:22003962 PMID:23591579 PMID:23791922 PMID:23836369 PMID:24469321 PMID:24525298 PMID:28975372 PMID:30768131 More...
|
|
NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Acrylamide results in increased expression of ATF3 protein] pyrazolanthrone inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of ATF3 protein]; pyrazolanthrone inhibits the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate results in increased phosphorylation of ATF3 protein] |
CTD |
PMID:22003962 PMID:25531190 PMID:33921748 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
EXP ISO |
pyrazolanthrone inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in increased expression of ATF4 mRNA] pyrazolanthrone inhibits the reaction [honokiol results in increased expression of ATF4 protein] |
CTD |
PMID:20920558 PMID:33550458 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [naphtho(1,2-b)furan-4,5-dione results in increased expression of BAD protein] |
CTD |
PMID:19747539 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bag3 |
BAG cochaperone 3 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of BAG3 mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of BAG3 protein] |
CTD |
PMID:22020323 |
|
NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [docetaxel results in increased activity of BAK1 protein] |
CTD |
PMID:17317842 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
[U 0126 co-treated with pyrazolanthrone] inhibits the reaction [fisetin results in increased expression of BAX protein]; [XMU-MP-1 co-treated with U 0126 co-treated with pyrazolanthrone] inhibits the reaction [fisetin results in increased expression of BAX protein]; MYC affects the reaction [pyrazolanthrone results in increased expression of BAX protein]; pyrazolanthrone affects the reaction [Methylmercury Compounds affects the localization of BAX protein]; pyrazolanthrone inhibits the reaction [3-oxo-29-noroleana-1,9(11),12-trien-2,20-dicarbonitrile results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; pyrazolanthrone inhibits the reaction [Docetaxel results in increased activity of BAX protein]; pyrazolanthrone inhibits the reaction [fisetin results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [Methylmercury Compounds inhibits the reaction [BAX protein binds to YWHAZ protein]]; pyrazolanthrone inhibits the reaction [nickel sulfate results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [Pt(O,O'-acac)(gamma-acac)(DMS) affects the localization of BAX protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased cleavage of BAX protein]; pyrazolanthrone inhibits the reaction [surfactin peptide results in increased expression of BAX protein]; pyrazolanthrone promotes the reaction [Arsenic Trioxide results in increased activity of and results in increased localization of BAX protein] pyrazolanthrone inhibits the reaction [Acetaminophen affects the localization of BAX protein]; pyrazolanthrone inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein] pyrazolanthrone inhibits the reaction [bakuchiol affects the localization of BAX protein]; pyrazolanthrone inhibits the reaction [cadmium acetate results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [Isoflurane results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of BAX protein] |
CTD |
PMID:14514659 PMID:15034932 PMID:16046226 PMID:16972261 PMID:17292878 PMID:17317842 PMID:19428505 PMID:19540902 PMID:19954742 PMID:20423716 PMID:21420390 PMID:24036456 PMID:24577723 PMID:25043952 PMID:29289695 PMID:30653946 PMID:31044527 PMID:33684387 PMID:33959992 PMID:34861471 PMID:34999165 PMID:35172196 PMID:35499276 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol results in increased expression of BBC3 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased expression of BBC3 protein] |
CTD |
PMID:30472098 PMID:32540572 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcas2 |
BCAS2, pre-mRNA processing factor |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Ozone results in increased expression of BCAS2 mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr 2:190,692,503...190,700,386
Ensembl chr 2:190,692,461...190,700,389
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases phosphorylation |
ISO EXP |
pyrazolanthrone inhibits the reaction [1,4-naphthoquinone analog results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [3-oxo-29-noroleana-1,9(11),12-trien-2,20-dicarbonitrile results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [6-(N,N-dimethylamino)-2-(naphthalene-1-yl)-4-quinazolinone results in increased phosphorylation of BCL2 protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of BCL2 protein]; pyrazolanthrone inhibits the reaction [Docetaxel results in increased phosphorylation of BCL2 protein]; pyrazolanthrone inhibits the reaction [fosbretabulin results in increased phosphorylation of BCL2 protein]; pyrazolanthrone inhibits the reaction [naphtho(1,2-b)furan-4,5-dione results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [pachastrissamine analog inhibits the reaction [BCL2 protein binds to BECN1 protein]]; pyrazolanthrone inhibits the reaction [Pt(O,O'-acac)(gamma-acac)(DMS) results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [surfactin peptide results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [trimethyltin chloride results in decreased expression of BCL2 protein] pyrazolanthrone inhibits the reaction [Cardiotoxins results in increased phosphorylation of BCL2 protein] pyrazolanthrone inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in decreased expression of BCL2 mRNA]; pyrazolanthrone inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of BCL2 protein modified form]; pyrazolanthrone inhibits the reaction [cadmium acetate results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in decreased expression of BCL2 protein]; pyrazolanthrone results in increased phosphorylation of and results in decreased activity of BCL2 protein pyrazolanthrone results in decreased phosphorylation of BCL2 protein |
CTD |
PMID:14724571 PMID:17317842 PMID:17786558 PMID:18412143 PMID:19428505 PMID:19540902 PMID:19747539 PMID:19954742 PMID:20166895 PMID:20920558 PMID:21420390 PMID:23212307 PMID:23423712 PMID:24036456 PMID:24321340 PMID:24577723 PMID:24833599 PMID:25043952 PMID:25446857 PMID:30472098 PMID:30653946 PMID:30871965 PMID:35123989 PMID:35172196 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO EXP |
[pyrazolanthrone co-treated with U 0126] inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein]; [XMU-MP-1 co-treated with pyrazolanthrone co-treated with U 0126] inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [[Sulindac co-treated with Arsenic Trioxide] results in increased phosphorylation of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [naphtho(1,2-b)furan-4,5-dione results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [nickel sulfate results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [pachastrissamine analog inhibits the reaction [BCL2L1 protein binds to BECN1 protein]] pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of BCL2L1 protein modified form] |
CTD |
PMID:18281123 PMID:19540902 PMID:19747539 PMID:20166895 PMID:31044527 PMID:35123989 PMID:35499276 More...
|
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of BCL2L11 protein] pyrazolanthrone inhibits the reaction [docetaxel results in increased degradation of BCL2L11 protein]; pyrazolanthrone inhibits the reaction [Lovastatin results in increased expression of BCL2L11 protein]; pyrazolanthrone inhibits the reaction [Nimustine results in increased expression of BCL2L11 mRNA]; pyrazolanthrone inhibits the reaction [temozolomide results in increased expression of BCL2L11 mRNA] |
CTD |
PMID:16166651 PMID:17317842 PMID:18766339 PMID:26418950 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [BDNF protein results in increased expression of SOD2 protein] |
CTD |
PMID:22261313 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Becn1 |
beclin 1 |
multiple interactions decreases expression |
EXP ISO |
pyrazolanthrone inhibits the reaction [Colistin results in increased expression of BECN1 protein]; pyrazolanthrone inhibits the reaction [decamethrin results in increased expression of BECN1 protein] pyrazolanthrone inhibits the reaction [pachastrissamine analog inhibits the reaction [BCL2 protein binds to BECN1 protein]]; pyrazolanthrone inhibits the reaction [pachastrissamine analog inhibits the reaction [BCL2L1 protein binds to BECN1 protein]]; pyrazolanthrone promotes the reaction [polyphyllin I results in increased expression of BECN1 protein] SP600125 decreases expression of protein in oxygen-glucose deprived rat neuronal PC12 cells |
CTD RGD |
PMID:26588882 PMID:28842171 PMID:31421117 PMID:35123989 PMID:27769861 |
RGD:329853763 |
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
EXP |
[pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased expression of BGLAP protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of BGLAP protein] |
CTD |
PMID:26136938 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
pyrazolanthrone promotes the reaction [arsenic trioxide results in increased cleavage of BID protein] |
CTD |
PMID:16972261 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
multiple interactions |
ISO |
pyrazolanthrone promotes the reaction [IL1A protein results in increased expression of BIRC2 mRNA] |
CTD |
PMID:12832416 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [arsenic trioxide results in decreased expression of BIRC5 protein]; pyrazolanthrone inhibits the reaction [naphtho(1,2-b)furan-4,5-dione results in decreased expression of BIRC5 protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in decreased expression of BIRC5 mRNA]; pyrazolanthrone inhibits the reaction [sodium arsenite results in decreased expression of BIRC5 protein] |
CTD |
PMID:16328441 PMID:19747539 PMID:21594580 PMID:22706169 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Cadmium results in increased expression of BNIP3 protein] |
CTD |
PMID:24824807 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of BNIP3L protein] |
CTD |
PMID:34861471 |
|
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased phosphorylation of CAMK2A protein] |
CTD |
PMID:21933187 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Capn1 |
calpain 1 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Isoflurane results in increased expression of CAPN1 protein] |
CTD |
PMID:29289695 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Capn2 |
calpain 2 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Isoflurane results in increased expression of CAPN2 protein] |
CTD |
PMID:29289695 |
|
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [irinotecan results in increased cleavage of CASP1 protein] pyrazolanthrone inhibits the reaction [APP protein results in increased expression of and results in increased cleavage of CASP1 protein] |
CTD |
PMID:26431797 PMID:28004443 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased cleavage of CASP12 protein] |
CTD |
PMID:24140863 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp2 |
caspase 2 |
decreases activity |
ISO |
pyrazolanthrone results in decreased activity of CASP2 protein |
CTD |
PMID:17317842 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity decreases activity increases expression |
ISO EXP |
[U 0126 co-treated with pyrazolanthrone] inhibits the reaction [fisetin results in increased cleavage of CASP3 protein]; [XMU-MP-1 co-treated with U 0126 co-treated with pyrazolanthrone] inhibits the reaction [fisetin results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [1,4-naphthoquinone analog results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in decreased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [2-aminodiphenyl results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [3-oxo-29-noroleana-1,9(11),12-trien-2,20-dicarbonitrile results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [5-((4-methylphenyl)methylene)-2-(phenylamino)-4(5H)-thiazolone results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [6-(N,N-dimethylamino)-2-(naphthalene-1-yl)-4-quinazolinone results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [8-bromo-7-methoxychrysin results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [[Arsenic Trioxide co-treated with Ethacrynic Acid] results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [[fludarabine co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [[Sulindac co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [Biological Products results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Chlorpyrifos results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [Citrinin results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [coronarin D results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [dehydroxymethylepoxyquinomicin results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [fisetin results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [flubendazole results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Indomethacin results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Ketoconazole results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [morusin results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Oxygen deficiency promotes the reaction [HBEGF protein mutant form results in increased activity of CASP3 protein]]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [Phytochemicals results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [polyphyllin I results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [Quercetin results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [rhoifolin results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased cleavage of CASP3 protein]; pyrazolanthrone promotes the reaction [dihydromyricetin results in increased cleavage of CASP3 protein]; pyrazolanthrone promotes the reaction [FAS protein results in increased cleavage of and results in increased activity of CASP3 protein]; pyrazolanthrone promotes the reaction [pachastrissamine analog results in increased cleavage of CASP3 protein]; pyrazolanthrone promotes the reaction [picrasidine I results in increased expression of CASP3 protein modified form]; pyrazolanthrone promotes the reaction [usnic acid results in increased activity of CASP3 protein] pyrazolanthrone results in increased activity of CASP3 protein pyrazolanthrone results in decreased activity of CASP3 protein 6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride promotes the reaction [pyrazolanthrone inhibits the reaction [Folic Acid results in increased activity of CASP3 protein]]; pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Cadmium results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Folic Acid results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [pseudolaric acid B results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Sodium Fluoride results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [TEMPO results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Tretinoin results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]; pyrazolanthrone promotes the reaction [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride inhibits the reaction [Folic Acid results in increased activity of CASP3 protein]] pyrazolanthrone inhibits the reaction [4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [bakuchiol results in increased activity of and results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [cadmium acetate results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased cleavage of and results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Carmustine results in increased activity of and results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [decamethrin results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Isoflurane results in increased expression of CASP3 protein modified form]; pyrazolanthrone inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [manganese chloride results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [Manganese results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [Manganese results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [nickel chloride results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Palmitic Acid results in increased expression of CASP3 mRNA]; pyrazolanthrone inhibits the reaction [Palmitic Acid results in increased expression of CASP3 protein]; pyrazolanthrone inhibits the reaction [satratoxin H results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Thrombin results in increased expression of and results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Vitamin K 3 results in increased cleavage of CASP3 protein]; pyrazolanthrone promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein]]; Taurine promotes the reaction [pyrazolanthrone inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]] pyrazolanthrone results in increased expression of CASP3 protein modified form |
CTD |
PMID:12393500 PMID:15034932 PMID:15095415 PMID:15254339 PMID:15501958 PMID:15767555 PMID:15831436 PMID:15850772 PMID:16061660 PMID:16310883 PMID:16322078 PMID:16357177 PMID:16712891 PMID:16787641 PMID:16843435 PMID:17292878 PMID:17341418 PMID:18281123 PMID:18703135 PMID:18767140 PMID:19193634 PMID:19361540 PMID:19631732 PMID:20632440 PMID:20830294 PMID:20920558 PMID:21165570 PMID:21295052 PMID:21600974 PMID:21843585 PMID:21843586 PMID:22654482 PMID:22863859 PMID:23082001 PMID:23212307 PMID:23405080 PMID:23416140 PMID:23578390 PMID:23836369 PMID:24036456 PMID:24111524 PMID:24157283 PMID:24577723 PMID:25043952 PMID:25078063 PMID:25305377 PMID:25446857 PMID:25882087 PMID:26588882 PMID:26630137 PMID:27539140 PMID:27841083 PMID:28383207 PMID:28391263 PMID:28474156 PMID:29289695 PMID:29968959 PMID:30259999 PMID:30871965 PMID:30928397 PMID:31044527 PMID:31421117 PMID:31447676 PMID:32574669 PMID:32652169 PMID:33035517 PMID:33684387 PMID:33922211 PMID:33959992 PMID:34861471 PMID:34894061 PMID:35123989 PMID:35172196 PMID:35383226 PMID:37244295 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP4 protein] |
CTD |
PMID:16357177 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp6 |
caspase 6 |
multiple interactions |
EXP ISO |
pyrazolanthrone inhibits the reaction [Vitamin K 3 results in increased activity of CASP6 protein]; pyrazolanthrone inhibits the reaction [Vitamin K 3 results in increased cleavage of CASP6 protein] pyrazolanthrone inhibits the reaction [dehydroxymethylepoxyquinomicin results in increased cleavage of CASP6 protein]; pyrazolanthrone inhibits the reaction [Indomethacin results in increased activity of CASP6 protein]; pyrazolanthrone inhibits the reaction [surfactin peptide results in increased cleavage of and results in increased activity of CASP6 protein] |
CTD |
PMID:15501958 PMID:16310883 PMID:17341418 PMID:19954742 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [ellipticine results in increased cleavage of and results in increased activity of CASP7 protein]; pyrazolanthrone promotes the reaction [dihydromyricetin results in increased cleavage of CASP7 protein]; pyrazolanthrone promotes the reaction [usnic acid results in increased activity of CASP7 protein] pyrazolanthrone inhibits the reaction [arsenic trioxide results in increased activity of CASP7 protein]; pyrazolanthrone inhibits the reaction [TEMPO results in increased activity of CASP7 protein] pyrazolanthrone inhibits the reaction [4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene results in increased cleavage of CASP7 protein]; pyrazolanthrone inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in increased cleavage of CASP7 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased cleavage of CASP7 protein]; pyrazolanthrone inhibits the reaction [nickel chloride results in increased activity of CASP7 protein] |
CTD |
PMID:20920558 PMID:21843585 PMID:21843586 PMID:23405080 PMID:24157283 PMID:25078063 PMID:25882087 PMID:27539140 PMID:33922211 More...
|
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [6-(N,N-dimethylamino)-2-(naphthalene-1-yl)-4-quinazolinone results in increased expression of CASP8 protein]; pyrazolanthrone inhibits the reaction [[Buthionine Sulfoximine co-treated with Arsenic Trioxide] results in increased cleavage of CASP8 protein]; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP8 protein]; pyrazolanthrone inhibits the reaction [Aminolevulinic Acid analog results in increased activity of CASP8 protein]; pyrazolanthrone inhibits the reaction [coronarin D results in increased expression of CASP8 protein modified form]; pyrazolanthrone inhibits the reaction [dehydroxymethylepoxyquinomicin results in increased cleavage of CASP8 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased cleavage of CASP8 protein]; pyrazolanthrone promotes the reaction [Arsenic Trioxide results in increased activity of CASP8 protein]; pyrazolanthrone promotes the reaction [FAS protein results in increased cleavage of and results in increased activity of CASP8 protein] |
CTD |
PMID:15501958 PMID:15767555 PMID:16061660 PMID:16972261 PMID:17145888 PMID:21138480 PMID:21165570 PMID:23212307 PMID:29968959 More...
|
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO EXP |
pyrazolanthrone inhibits the reaction [5-((4-methylphenyl)methylene)-2-(phenylamino)-4(5H)-thiazolone results in increased cleavage of CASP9 protein]; pyrazolanthrone inhibits the reaction [6-(N,N-dimethylamino)-2-(naphthalene-1-yl)-4-quinazolinone results in increased expression of CASP9 protein]; pyrazolanthrone inhibits the reaction [Aminolevulinic Acid analog results in increased activity of CASP9 protein]; pyrazolanthrone inhibits the reaction [coronarin D results in increased expression of CASP9 protein modified form]; pyrazolanthrone inhibits the reaction [dehydroxymethylepoxyquinomicin results in increased cleavage of CASP9 protein]; pyrazolanthrone inhibits the reaction [Indomethacin results in increased activity of CASP9 protein]; pyrazolanthrone inhibits the reaction [morusin results in increased cleavage of CASP9 protein]; pyrazolanthrone inhibits the reaction [Pt(O,O'-acac)(gamma-acac)(DMS) results in increased activity of CASP9 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased cleavage of CASP9 protein]; pyrazolanthrone promotes the reaction [dihydromyricetin results in increased cleavage of CASP9 protein] pyrazolanthrone results in increased activity of CASP9 protein pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal results in increased activity of CASP9 protein]; pyrazolanthrone inhibits the reaction [Cardiotoxins results in increased cleavage of CASP9 protein] pyrazolanthrone inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in increased cleavage of CASP9 protein]; pyrazolanthrone inhibits the reaction [nickel chloride results in increased activity of CASP9 protein]; pyrazolanthrone inhibits the reaction [Vitamin K 3 results in increased cleavage of CASP9 protein] |
CTD |
PMID:15034932 PMID:15501958 PMID:15831436 PMID:16310883 PMID:16322078 PMID:17341418 PMID:17786558 PMID:20920558 PMID:21138480 PMID:21165570 PMID:21420390 PMID:21843586 PMID:23212307 PMID:27539140 PMID:29968959 PMID:33035517 More...
|
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [rhoifolin results in increased activity of CAT protein]; pyrazolanthrone promotes the reaction [Pyrogallol results in decreased expression of CAT protein] |
CTD |
PMID:20191265 PMID:35383226 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [Cocaine results in increased expression of CCL2 protein]; pyrazolanthrone inhibits the reaction [Cyclosporine results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [Cyclosporine results in increased expression of CCL2 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]]; pyrazolanthrone inhibits the reaction [Palmitates results in increased secretion of CCL2 protein]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL2 protein]; pyrazolanthrone promotes the reaction [Ozone results in increased expression of CCL2 mRNA] pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased secretion of CCL2 protein] pyrazolanthrone inhibits the reaction [Allopurinol results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein] |
CTD |
PMID:17460151 PMID:18303122 PMID:20354174 PMID:20712904 PMID:23958496 PMID:26641773 PMID:26862037 PMID:28087833 PMID:28505368 More...
|
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Cyclosporine results in increased expression of CCL5 mRNA]; pyrazolanthrone inhibits the reaction [Tacrolimus results in increased expression of CCL5 mRNA] |
CTD |
PMID:23958496 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
[pyrazolanthrone co-treated with U 0126] inhibits the reaction [fisetin results in decreased expression of CCN2 protein]; [XMU-MP-1 co-treated with pyrazolanthrone co-treated with U 0126] inhibits the reaction [fisetin results in decreased expression of CCN2 protein]; pyrazolanthrone inhibits the reaction [fisetin results in decreased expression of CCN2 protein] |
CTD |
PMID:31044527 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [6-(N,N-dimethylamino)-2-(naphthalene-1-yl)-4-quinazolinone results in increased expression of CCNB1 protein] |
CTD |
PMID:23212307 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
ISO |
pyrazolanthrone inhibits the reaction [7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of CCND1 mRNA]; pyrazolanthrone inhibits the reaction [kahweol results in decreased expression of CCND1 protein]; pyrazolanthrone inhibits the reaction [kahweol results in increased phosphorylation of CCND1 protein] pyrazolanthrone results in decreased expression of CCND1 protein |
CTD |
PMID:18593901 PMID:19801633 PMID:27424123 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Silicon Dioxide results in increased expression of CCR2 protein] |
CTD |
PMID:26163174 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Cd14 |
CD14 molecule |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Calcitriol results in increased expression of CD14 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 protein] |
CTD |
PMID:14729647 PMID:18180316 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd207 |
CD207 molecule |
multiple interactions decreases expression |
ISO |
pyrazolanthrone promotes the reaction [nickel sulfate results in decreased expression of CD207 protein] pyrazolanthrone results in decreased expression of CD207 protein |
CTD |
PMID:15588916 |
|
NCBI chr 4:116,155,229...116,161,587
Ensembl chr 4:116,155,212...116,161,518
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in decreased expression of CD36 mRNA] |
CTD |
PMID:21873422 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd80 |
Cd80 molecule |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Fungal Polysaccharides results in increased expression of CD80 protein] |
CTD |
PMID:28235615 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Fungal Polysaccharides results in increased expression of CD86 protein] |
CTD |
PMID:28235615 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdc25c |
cell division cycle 25C |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [5-(2,4-dihydroxybenzylidene)-2-(phenylimino)-1,3-thiazolidin affects the expression of CDC25C protein] |
CTD |
PMID:16179969 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression multiple interactions |
ISO |
pyrazolanthrone results in decreased expression of CDH1 protein pyrazolanthrone inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; pyrazolanthrone promotes the reaction [nickel sulfate results in decreased expression of CDH1 protein] 6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride promotes the reaction [pyrazolanthrone inhibits the reaction [Folic Acid results in decreased expression of CDH1 protein]]; pyrazolanthrone inhibits the reaction [Folic Acid results in decreased expression of CDH1 protein]; pyrazolanthrone promotes the reaction [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride inhibits the reaction [Folic Acid results in decreased expression of CDH1 protein]] |
CTD |
PMID:15588916 PMID:31447676 PMID:33396024 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh5 |
cadherin 5 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Varenicline results in decreased expression of CDH5] |
CTD |
PMID:28842382 |
|
NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions decreases expression |
ISO |
pyrazolanthrone inhibits the reaction [6-(N,N-dimethylamino)-2-(naphthalene-1-yl)-4-quinazolinone results in increased expression of CDK1 protein] pyrazolanthrone results in decreased expression of CDK1 protein |
CTD |
PMID:18593901 PMID:23212307 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions decreases activity |
ISO |
pyrazolanthrone inhibits the reaction [naphtho(1,2-b)furan-4,5-dione results in decreased expression of CDK2 protein] pyrazolanthrone results in decreased activity of CDK2 protein |
CTD |
PMID:12534346 PMID:19747539 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [[sodium arsenite co-treated with lead acetate co-treated with Cadmium Chloride] results in increased phosphorylation of CDK5 protein]; pyrazolanthrone inhibits the reaction [troglitazone results in increased phosphorylation of CDK5 protein] |
CTD |
PMID:24481447 |
|
NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [resveratrol results in decreased expression of CDK5R1 mRNA] |
CTD |
PMID:21736731 |
|
NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO EXP |
pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased expression of CDKN1A protein]; pyrazolanthrone inhibits the reaction [tributyltin results in increased expression of CDKN1A protein]; pyrazolanthrone promotes the reaction [Arsenic Trioxide results in increased expression of CDKN1A mRNA]; pyrazolanthrone promotes the reaction [Arsenic Trioxide results in increased expression of CDKN1A protein]; pyrazolanthrone promotes the reaction [EGF protein results in increased expression of CDKN1A mRNA] pyrazolanthrone results in increased expression of CDKN1A protein pyrazolanthrone promotes the reaction [Diethylnitrosamine results in increased expression of CDKN1A protein] |
CTD |
PMID:15961274 PMID:16061660 PMID:16283431 PMID:19418558 PMID:31734849 PMID:36319700 More...
|
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Particulate Matter results in increased methylation of CDKN2A promoter] |
CTD |
PMID:22355787 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPA protein] |
CTD |
PMID:24376792 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Calcitriol results in increased expression of CEBPB mRNA]; pyrazolanthrone inhibits the reaction [Calcitriol results in increased expression of CEBPB protein]; pyrazolanthrone inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPB protein] |
CTD |
PMID:14729647 PMID:24376792 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPD protein] |
CTD |
PMID:24376792 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Ces3a |
carboxylesterase 3a |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Ozone results in increased expression of CES3 mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr19:32,992,386...33,000,562
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [sodium arsenite results in increased phosphorylation of CHUK protein] |
CTD |
PMID:19616567 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cldn4 |
claudin 4 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased expression of CLDN4 mRNA]; pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased expression of CLDN4 protein] |
CTD |
PMID:23816505 |
|
NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436
|
|
G |
Cpeb1 |
cytoplasmic polyadenylation element binding protein 1 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased phosphorylation of CPEB1 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of CPEB1 mRNA] |
CTD |
PMID:21620800 |
|
NCBI chr 1:135,300,048...135,407,688
Ensembl chr 1:135,300,461...135,409,760
|
|
G |
Cpeb4 |
cytoplasmic polyadenylation element binding protein 4 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [sodium arsenite promotes the reaction [CPEB4 protein binds to SORBS3 protein]] |
CTD |
PMID:25237887 |
|
NCBI chr10:15,717,794...15,780,482
Ensembl chr10:15,717,794...15,780,603
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
increases expression multiple interactions |
ISO |
pyrazolanthrone results in increased expression of CPT1B mRNA pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in decreased expression of CPT1B mRNA] |
CTD |
PMID:21873422 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
decreases phosphorylation multiple interactions |
ISO EXP |
pyrazolanthrone results in decreased phosphorylation of CREB1 protein pyrazolanthrone inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]; pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:25605016 PMID:28087833 PMID:32920012 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of CRH mRNA] |
CTD |
PMID:28189027 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Cs |
citrate synthase |
multiple interactions |
ISO |
pyrazolanthrone affects the reaction [triethylene glycol dimethacrylate affects the activity of CS protein] |
CTD |
PMID:33684387 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Particulate Matter results in increased secretion of CSF2 protein] |
CTD |
PMID:19460412 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csnk1d |
casein kinase 1, delta |
decreases activity |
ISO |
pyrazolanthrone results in decreased activity of CSNK1D protein |
CTD |
PMID:12534346 |
|
NCBI chr10:106,221,992...106,256,620
Ensembl chr10:106,221,992...106,256,614
|
|
G |
Cst3 |
cystatin C |
multiple interactions |
ISO |
6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride promotes the reaction [pyrazolanthrone inhibits the reaction [Folic Acid results in increased expression of CST3 protein]]; pyrazolanthrone inhibits the reaction [Folic Acid results in increased expression of CST3 protein]; pyrazolanthrone promotes the reaction [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride inhibits the reaction [Folic Acid results in increased expression of CST3 protein]] |
CTD |
PMID:31447676 |
|
NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822
|
|
G |
Ctf1 |
cardiotrophin 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [cobaltous chloride results in increased expression of CTF1 protein]; pyrazolanthrone inhibits the reaction [Vitamin K 3 results in increased expression of CTF1 protein] |
CTD |
PMID:16507596 |
|
NCBI chr 1:182,328,035...182,336,346
Ensembl chr 1:182,328,090...182,333,335
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased secretion of CXCL1 protein] |
CTD |
PMID:28087833 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of CXCL10 mRNA] |
CTD |
PMID:12832416 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl16 |
C-X-C motif chemokine ligand 16 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [cypermethrin results in increased expression of CXCL16 protein] |
CTD |
PMID:35512476 |
|
NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of CXCL2 protein] |
CTD |
PMID:21507677 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Glucose results in increased expression of CYBA protein] |
CTD |
PMID:22245600 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in increased expression of CYCS protein]; pyrazolanthrone inhibits the reaction [surfactin peptide affects the localization of CYCS protein]; pyrazolanthrone promotes the reaction [Arsenic Trioxide affects the localization of CYCS protein] pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal affects the localization of CYCS protein] |
CTD |
PMID:16322078 PMID:16972261 PMID:19954742 PMID:30653946 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cygb |
cytoglobin |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole results in increased expression of CYGB mRNA] |
CTD |
PMID:25781201 |
|
NCBI chr10:101,877,675...101,887,442
Ensembl chr10:101,877,676...101,887,442
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [bisphenol A results in increased expression of CYP11A1 mRNA]; pyrazolanthrone inhibits the reaction [bisphenol A results in increased expression of CYP11A1 protein] pyrazolanthrone inhibits the reaction [nickel sulfate results in decreased expression of CYP11A1 mRNA]; pyrazolanthrone inhibits the reaction [nickel sulfate results in decreased expression of CYP11A1 protein] |
CTD |
PMID:26209791 PMID:28697429 PMID:29567110 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO EXP |
pyrazolanthrone results in increased expression of CYP17A1 mRNA pyrazolanthrone inhibits the reaction [FGF19 protein results in decreased expression of CYP17A1 mRNA] pyrazolanthrone inhibits the reaction [nickel sulfate results in decreased expression of CYP17A1 mRNA]; pyrazolanthrone inhibits the reaction [nickel sulfate results in decreased expression of CYP17A1 protein] |
CTD |
PMID:16269825 PMID:29567110 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [LEP protein results in increased expression of CYP19A1 mRNA]; pyrazolanthrone inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased expression of CYP19A1 protein] pyrazolanthrone inhibits the reaction [bisphenol A results in increased expression of and results in increased activity of CYP19A1 protein] pyrazolanthrone inhibits the reaction [bisphenol A results in increased expression of CYP19A1 mRNA]; pyrazolanthrone inhibits the reaction [bisphenol A results in increased expression of CYP19A1 protein] |
CTD |
PMID:20096755 PMID:20678559 PMID:28571770 PMID:28697429 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression decreases expression |
ISO |
pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; resveratrol inhibits the reaction [pyrazolanthrone results in increased expression of CYP1A1 mRNA] pyrazolanthrone inhibits the reaction [Copper results in increased expression of CYP1A1 mRNA]; pyrazolanthrone inhibits the reaction [Lead results in increased expression of CYP1A1 mRNA]; pyrazolanthrone inhibits the reaction [Mercury results in increased expression of CYP1A1 mRNA]; pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]; pyrazolanthrone promotes the reaction [Copper inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; pyrazolanthrone promotes the reaction [Lead inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]]; pyrazolanthrone promotes the reaction [Mercury inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]] pyrazolanthrone results in decreased expression of CYP1A1 mRNA |
CTD |
PMID:17959153 PMID:18078826 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression multiple interactions |
ISO |
pyrazolanthrone results in increased expression of CYP1A2 mRNA pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA]; resveratrol inhibits the reaction [pyrazolanthrone results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:17959153 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; pyrazolanthrone inhibits the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA] |
CTD |
PMID:22486562 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Calcitriol results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:17965521 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Tretinoin results in decreased expression of CYP7A1 mRNA]; pyrazolanthrone inhibits the reaction [Tretinoin results in decreased expression of CYP7A1 protein] |
CTD |
PMID:30709899 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [dihydrocapsaicin results in increased expression of DDIT3 protein]; pyrazolanthrone inhibits the reaction [honokiol results in increased expression of DDIT3 protein]; pyrazolanthrone inhibits the reaction [Indomethacin results in increased expression of DDIT3 protein]; pyrazolanthrone inhibits the reaction [Leflunomide results in increased expression of DDIT3 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of DDIT3 protein]; pyrazolanthrone inhibits the reaction [Resveratrol results in increased expression of DDIT3 mRNA]; pyrazolanthrone inhibits the reaction [Resveratrol results in increased expression of DDIT3 protein]; pyrazolanthrone inhibits the reaction [tanshinone results in increased expression of DDIT3 protein] pyrazolanthrone inhibits the reaction [4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene results in increased expression of DDIT3 protein]; pyrazolanthrone inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in increased expression of DDIT3 mRNA]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased expression of DDIT3 protein] pyrazolanthrone inhibits the reaction [alpha-naphthoflavone results in increased expression of DDIT3 protein] |
CTD |
PMID:17049495 PMID:17341418 PMID:19139269 PMID:20920558 PMID:24612139 PMID:26203587 PMID:28988120 PMID:30508555 PMID:31348969 PMID:33550458 PMID:33922211 More...
|
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
multiple interactions |
ISO |
[Sulfasalazine co-treated with pyrazolanthrone] inhibits the reaction [IL1B protein results in decreased expression of DIO1 mRNA] |
CTD |
PMID:16614379 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of DNMT1 protein] |
CTD |
PMID:22355787 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
multiple interactions |
EXP |
[pyrazolanthrone co-treated with cypermethrin] results in decreased expression of DNMT3A protein |
CTD |
PMID:34794910 |
|
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
multiple interactions |
EXP |
[pyrazolanthrone co-treated with cypermethrin] results in decreased expression of DNMT3B protein |
CTD |
PMID:34794910 |
|
NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
Doc2b |
double C2 domain beta |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Ozone results in increased expression of DOC2B mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr10:60,628,029...60,653,267
Ensembl chr10:60,628,029...60,653,267
|
|
G |
Dyrk1a |
dual specificity tyrosine phosphorylation regulated kinase 1A |
decreases activity |
ISO |
pyrazolanthrone results in decreased activity of DYRK1A protein |
CTD |
PMID:12534346 |
|
NCBI chr11:33,890,706...34,009,420
Ensembl chr11:33,890,490...34,009,420
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Glucose results in increased expression of EDN1 mRNA] |
CTD |
PMID:24376792 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of EDNRA mRNA]; pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of EDNRA protein] |
CTD |
PMID:20561571 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]; pyrazolanthrone inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]; pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]; pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]; pyrazolanthrone inhibits the reaction [Smoke analog results in increased expression of EDNRB protein] |
CTD |
PMID:20561571 PMID:20716444 PMID:26496744 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [arsenite results in increased expression of and results in increased secretion of EGF protein]; pyrazolanthrone inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Cisplatin]]; pyrazolanthrone inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; pyrazolanthrone inhibits the reaction [EGF protein results in increased secretion of MUC5AC protein]; pyrazolanthrone promotes the reaction [EGF protein results in increased expression of CDKN1A mRNA] |
CTD |
PMID:15961274 PMID:21613822 PMID:22766066 PMID:36343453 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO EXP |
pyrazolanthrone results in decreased expression of EGFR mRNA; pyrazolanthrone results in decreased expression of EGFR protein |
CTD |
PMID:15923621 PMID:18332871 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Curcumin results in increased expression of EGR1 protein] pyrazolanthrone inhibits the reaction [arsenic trioxide results in increased expression of EGR1 mRNA] |
CTD |
PMID:15688020 PMID:18316600 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif2ak2 |
eukaryotic translation initiation factor 2-alpha kinase 2 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased cleavage of EIF2AK2 protein] |
CTD |
PMID:32574669 |
|
NCBI chr 6:16,189,000...16,224,972
Ensembl chr 6:16,188,979...16,224,971
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Anisomycin results in increased phosphorylation of ELK1 protein]; pyrazolanthrone inhibits the reaction [Curcumin results in increased phosphorylation of ELK1 protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:12660819 PMID:18316600 PMID:21642427 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Endog |
endonuclease G |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [cadmium acetate affects the localization of ENDOG protein] |
CTD |
PMID:24577723 |
|
NCBI chr 3:13,449,113...13,451,715
Ensembl chr 3:13,449,086...13,451,932
|
|
G |
Epor |
erythropoietin receptor |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [testosterone-3-carboxymethyloxime-bovine serum albumin conjugate results in increased expression of EPOR mRNA] |
CTD |
PMID:20189893 |
|
NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [ERBB2 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CXCL8 mRNA]]; pyrazolanthrone inhibits the reaction [ERBB2 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased secretion of CXCL8 protein]] |
CTD |
PMID:33396024 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [dihydrocapsaicin results in increased expression of ERN1 protein] |
CTD |
PMID:19139269 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [bisphenol S results in increased phosphorylation of ESR2 protein] |
CTD |
PMID:38301581 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Etfa |
electron transfer flavoprotein subunit alpha |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [tert-Butylhydroperoxide results in increased expression of ETFA protein] |
CTD |
PMID:24394546 |
|
NCBI chr 8:55,835,115...55,891,890
Ensembl chr 8:55,835,134...55,891,969
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Arsenicals results in increased phosphorylation of EZH2 protein] |
CTD |
PMID:23255093 |
|
NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
|
|
G |
F2 |
coagulation factor II, thrombin |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein] |
CTD |
PMID:19944065 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [[Paclitaxel co-treated with F2 protein] results in increased expression of F3 protein]; pyrazolanthrone inhibits the reaction [Histamine results in increased expression of F3]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of F3 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of F3 mRNA] |
CTD |
PMID:16009787 PMID:19944065 PMID:20118172 PMID:27556861 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fadd |
Fas associated via death domain |
multiple interactions decreases phosphorylation |
ISO |
pyrazolanthrone inhibits the reaction [Aminolevulinic Acid analog results in increased phosphorylation of FADD protein]; pyrazolanthrone inhibits the reaction [Paclitaxel results in increased phosphorylation of FADD protein]; pyrazolanthrone inhibits the reaction [polyphenon E results in increased phosphorylation of FADD protein] pyrazolanthrone results in decreased phosphorylation of FADD protein |
CTD |
PMID:16450001 PMID:21138480 PMID:23285096 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression increases activity |
ISO |
pyrazolanthrone inhibits the reaction [FGF7 protein results in increased expression of FAS protein]; pyrazolanthrone promotes the reaction [FAS protein results in increased cleavage of and results in increased activity of CASP3 protein]; pyrazolanthrone promotes the reaction [FAS protein results in increased cleavage of and results in increased activity of CASP8 protein] pyrazolanthrone results in increased expression of FAS protein pyrazolanthrone results in increased activity of FAS protein |
CTD |
PMID:16061660 PMID:16162944 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
pyrazolanthrone affects the reaction [temozolomide results in increased expression of FASLG mRNA]; pyrazolanthrone inhibits the reaction [[sorafenib co-treated with Vitamin K 1] results in increased expression of FASLG protein]; pyrazolanthrone inhibits the reaction [Nimustine results in increased expression of FASLG mRNA]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of FASLG protein] |
CTD |
PMID:20301194 PMID:21165570 PMID:26418950 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fbxo32 |
F-box protein 32 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Indican results in increased expression of FBXO32 protein] |
CTD |
PMID:30849338 |
|
NCBI chr 7:89,731,428...89,764,997
Ensembl chr 7:89,730,232...89,765,436
|
|
G |
Fem1b |
fem-1 homolog B |
multiple interactions |
ISO |
pyrazolanthrone promotes the reaction [Ozone results in increased expression of FEM1B mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr 8:63,265,301...63,278,577
Ensembl chr 8:63,265,301...63,278,577
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [FGF1 protein results in increased expression of SPP1 mRNA] |
CTD |
PMID:15121739 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [FGF19 protein results in decreased expression of CYP17A1 mRNA]; pyrazolanthrone inhibits the reaction [FGF19 protein results in decreased expression of PON1 mRNA] |
CTD |
PMID:16269825 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [hydroxyethyl methacrylate results in increased secretion of FGF2 protein]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of FGF2 mRNA]; pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA] pyrazolanthrone inhibits the reaction [FGF2 protein results in increased secretion of TNFRSF11B protein] pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein] |
CTD |
PMID:12832416 PMID:19176594 PMID:25290095 PMID:26800359 PMID:28087833 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [FGF7 protein results in increased expression of FAS protein]; pyrazolanthrone inhibits the reaction [FGF7 protein results in increased expression of SCD protein]; pyrazolanthrone inhibits the reaction [FGF7 protein results in increased expression of SREBF1 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased secretion of FGF7 protein] |
CTD |
PMID:15677771 PMID:16162944 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride promotes the reaction [pyrazolanthrone inhibits the reaction [Folic Acid results in increased expression of FN1 protein]]; pyrazolanthrone inhibits the reaction [Folic Acid results in increased expression of FN1 protein] |
CTD |
PMID:31447676 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO EXP |
[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one co-treated with 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole co-treated with pyrazolanthrone] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of FOS protein]; pyrazolanthrone inhibits the reaction [2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased phosphorylation of FOS protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of FOS protein]; pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of FOS protein] pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased expression of and results in increased phosphorylation of FOS protein]; pyrazolanthrone inhibits the reaction [Patulin results in increased expression of FOS protein] |
CTD |
PMID:22020770 PMID:24469321 PMID:24967690 PMID:28087833 PMID:34896196 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of FOSL1 mRNA]; pyrazolanthrone inhibits the reaction [Vehicle Emissions results in increased expression of FOSL1 mRNA] |
CTD |
PMID:14565943 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased phosphorylation of FOXO1 protein] |
CTD |
PMID:26385185 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [cordycepin results in decreased phosphorylation of and affects the localization of FOXO3 protein]; pyrazolanthrone inhibits the reaction [Ethanol results in increased phosphorylation of FOXO3 protein]; pyrazolanthrone inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased phosphorylation of FOXO3 protein] |
CTD |
PMID:26470730 PMID:28099944 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [FSHB protein results in increased abundance of Estradiol]; pyrazolanthrone inhibits the reaction [FSHB protein results in increased abundance of Progesterone] |
CTD |
PMID:22067323 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gabpa |
GA binding protein transcription factor subunit alpha |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Gallic Acid results in increased expression of GABPA protein] |
CTD |
PMID:16308312 |
|
NCBI chr11:23,888,586...23,917,612
Ensembl chr11:23,888,815...23,917,605
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of GADD45A protein]; troglitazone inhibits the reaction [pyrazolanthrone results in increased expression of GADD45A mRNA]; troglitazone inhibits the reaction [pyrazolanthrone results in increased expression of GADD45A protein] pyrazolanthrone inhibits the reaction [Excitatory Amino Acid Agents results in increased expression of GADD45A mRNA] |
CTD |
PMID:15064713 PMID:20955365 PMID:25469469 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of GADD45B mRNA]; pyrazolanthrone inhibits the reaction [sorafenib results in increased expression of GADD45B protein] |
CTD |
PMID:21062976 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Galnt3 |
polypeptide N-acetylgalactosaminyltransferase 3 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Cadmium results in increased expression of GALNT3 mRNA] |
CTD |
PMID:24614234 |
|
NCBI chr 3:50,742,500...50,779,266
Ensembl chr 3:50,742,512...50,766,268
|
|
G |
Gata2 |
GATA binding protein 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of GATA2 protein] |
CTD |
PMID:23940812 |
|
NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of GCH1 mRNA] |
CTD |
PMID:12832416 |
|
NCBI chr15:20,404,267...20,437,727
Ensembl chr15:20,402,527...20,437,698
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [[clivorine co-treated with Quercetin] results in increased expression of GCLC mRNA]; pyrazolanthrone inhibits the reaction [cinnamaldehyde results in increased expression of GCLC protein]; pyrazolanthrone inhibits the reaction [Quercetin promotes the reaction [Acetaminophen results in increased expression of GCLC mRNA]]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of GCLC mRNA]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of GCLC protein] pyrazolanthrone inhibits the reaction [Ozone results in increased expression of GCLC mRNA]; pyrazolanthrone promotes the reaction [arsenite results in increased expression of GCLC mRNA] |
CTD |
PMID:17460151 PMID:19328227 PMID:21469739 PMID:25881548 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions decreases activity |
ISO |
pyrazolanthrone inhibits the reaction [[Acetaminophen co-treated with Quercetin] results in increased expression of GCLM mRNA]; pyrazolanthrone inhibits the reaction [Quercetin inhibits the reaction [clivorine results in decreased expression of GCLM mRNA]]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of GCLM mRNA]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of GCLM protein] pyrazolanthrone results in decreased activity of GCLM protein |
CTD |
PMID:16972261 PMID:25881548 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions |
ISO |
pyrazolanthrone promotes the reaction [silybin results in increased expression of GDF15 protein] |
CTD |
PMID:24440808 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [deoxynivalenol results in decreased expression of GH1 mRNA]; pyrazolanthrone inhibits the reaction [deoxynivalenol results in decreased expression of GH1 protein] |
CTD |
PMID:26141394 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
EXP ISO |
pyrazolanthrone inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of GJA1 protein]; pyrazolanthrone inhibits the reaction [Amphetamine results in increased expression of GJA1 protein]; pyrazolanthrone inhibits the reaction [Indican results in decreased expression of and affects the localization of GJA1 protein]; pyrazolanthrone inhibits the reaction [Indican results in decreased expression of GJA1 mRNA] pyrazolanthrone inhibits the reaction [resveratrol results in increased expression of GJA1 protein] |
CTD |
PMID:15194466 PMID:24449132 PMID:32045570 PMID:36863560 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased activity of GLB1 protein]; pyrazolanthrone promotes the reaction [SB 203580 inhibits the reaction [Arsenic Trioxide results in increased activity of GLB1 protein]]; SB 203580 promotes the reaction [pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased activity of GLB1 protein]] |
CTD |
PMID:31734849 |
|
NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Acetaminophen results in increased activity of GOT1 protein] |
CTD |
PMID:33959992 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gp1ba |
glycoprotein Ib platelet subunit alpha |
multiple interactions |
ISO |
pyrazolanthrone promotes the reaction [THPO protein results in increased expression of GP1BA protein] |
CTD |
PMID:20523355 |
|
NCBI chr10:55,352,938...55,355,804
Ensembl chr10:55,352,899...55,356,774
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein] pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of GPT protein] pyrazolanthrone inhibits the reaction [Acetaminophen results in increased activity of GPT protein] |
CTD |
PMID:20166895 PMID:26218279 PMID:33959992 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Acetaminophen results in decreased activity of GPX3 protein] |
CTD |
PMID:33959992 |
|
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Acetaminophen results in decreased expression of GSTA1 mRNA]; pyrazolanthrone inhibits the reaction [Acetaminophen results in decreased expression of GSTA1 protein] |
CTD |
PMID:33959992 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gypa |
glycophorin A |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of GYPA protein] |
CTD |
PMID:20523355 |
|
NCBI chr19:27,450,304...27,465,940
Ensembl chr19:27,450,308...27,465,822
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [4-methoxy-2,2,6,6-tetramethylpiperidinyl-1-oxy results in increased phosphorylation of H2AX protein]; pyrazolanthrone inhibits the reaction [Resveratrol results in increased phosphorylation of H2AX protein] |
CTD |
PMID:25619392 PMID:28993908 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
H3f4 |
H3.4 histone, cluster member |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [5-(2,4-dihydroxybenzylidene)-2-(phenylimino)-1,3-thiazolidin results in increased phosphorylation of H3-4 protein] |
CTD |
PMID:16179969 |
|
NCBI chr10:43,740,702...43,741,262
|
|
G |
Hat1 |
histone acetyltransferase 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Quercetin results in increased activity of HAT1 protein] |
CTD |
PMID:21165570 |
|
NCBI chr 3:56,217,344...56,265,021
Ensembl chr 3:56,217,342...56,275,517
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Oxygen deficiency promotes the reaction [HBEGF protein mutant form results in increased activity of CASP3 protein]]; pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased expression of HBEGF mRNA] |
CTD |
PMID:19193634 PMID:26800359 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [andrographolide results in decreased expression of HIF1A protein]; pyrazolanthrone inhibits the reaction [manganese chloride results in increased expression of and results in increased activity of and results in increased stability of HIF1A protein] |
CTD |
PMID:20152896 PMID:28651835 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Silicon Dioxide results in increased expression of HMGB1 protein] |
CTD |
PMID:27616297 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases expression |
ISO EXP |
pyrazolanthrone inhibits the reaction [10-nitro-oleic acid results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [3-O-caffeoyl-1-methylquinic acid results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [[3-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [butein results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [cinnamaldehyde results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [iron protoporphyrin IX results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [lead acetate results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [pachastrissamine analog results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [Potassium Dichromate results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [Quercetin inhibits the reaction [Acetaminophen results in decreased expression of HMOX1 mRNA]]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [Sulindac promotes the reaction [Arsenic Trioxide results in increased expression of HMOX1 protein]]; pyrazolanthrone inhibits the reaction [tetrachlorobenzoquinone results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased expression of HMOX1 protein] pyrazolanthrone results in decreased expression of HMOX1 protein pyrazolanthrone inhibits the reaction [10-nitro-oleic acid results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [10-nitro-oleic acid results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [Copper results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [Lead results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [Mercury results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [Plant Extracts results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [Triclosan results in increased expression of HMOX1 protein]; pyrazolanthrone promotes the reaction [Quercetin analog results in increased expression of HMOX1 mRNA] pyrazolanthrone results in decreased expression of HMOX1 mRNA pyrazolanthrone inhibits the reaction [Acrylamide results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [aureusidin results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [Nitroprusside results in increased expression of HMOX1 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of HMOX1 mRNA]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of HMOX1 mRNA] |
CTD |
PMID:12637567 PMID:16171798 PMID:16439612 PMID:16631525 PMID:18078826 PMID:18289802 PMID:18332044 PMID:18404528 PMID:18636201 PMID:21469739 PMID:22056766 PMID:23318726 PMID:23535287 PMID:23845594 PMID:24140437 PMID:24423726 PMID:25449124 PMID:25881548 PMID:26291278 PMID:26385185 PMID:26404762 PMID:26542248 PMID:27393035 PMID:27777014 PMID:28087833 PMID:29426002 PMID:31790703 PMID:34160118 PMID:35123989 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf1a |
HNF1 homeobox A |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Acetaminophen results in decreased expression of HNF1A mRNA]; pyrazolanthrone inhibits the reaction [Acetaminophen results in decreased expression of HNF1A protein] |
CTD |
PMID:33959992 |
|
NCBI chr12:41,638,536...41,672,806
Ensembl chr12:41,645,587...41,672,104
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
increases expression multiple interactions |
ISO |
pyrazolanthrone results in increased expression of HNF4A mRNA pyrazolanthrone inhibits the reaction [TNF protein results in decreased expression of HNF4A mRNA] |
CTD |
PMID:19883121 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Hpx |
hemopexin |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Ozone results in increased expression of HPX mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328
|
|
G |
Hrk |
harakiri, BCL2 interacting protein |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of HRK mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of HRK protein] |
CTD |
PMID:35172196 |
|
NCBI chr12:38,387,484...38,409,652
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [nickel sulfate results in decreased expression of HSD17B3 mRNA] |
CTD |
PMID:29567110 |
|
NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [arsenic trioxide results in increased phosphorylation of HSF1 protein] |
CTD |
PMID:15978632 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in increased expression of HSP90B1 mRNA] |
CTD |
PMID:20920558 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased expression of HSPA1A protein] |
CTD |
PMID:28087833 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP ISO |
pyrazolanthrone inhibits the reaction [4-methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene results in increased expression of HSPA5 protein]; pyrazolanthrone inhibits the reaction [[cupric chloride binds to pyrrolidine dithiocarbamic acid] which results in increased expression of HSPA5 mRNA] pyrazolanthrone inhibits the reaction [honokiol results in increased expression of HSPA5 protein]; pyrazolanthrone inhibits the reaction [Indomethacin results in increased expression of HSPA5 protein] |
CTD |
PMID:17341418 PMID:20920558 PMID:33550458 PMID:33922211 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa6l-ps1 |
heat shock protein family A (Hsp70) member 6 like, pseudogene 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased expression of HSPA6 mRNA]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased expression of HSPA6 protein] |
CTD |
PMID:15978632 |
|
NCBI chr13:83,273,176...83,274,317
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
multiple interactions |
ISO |
[sodium arsenite co-treated with pyrazolanthrone] promotes the reaction [HSPA9 protein binds to TP53 protein modified form] |
CTD |
PMID:22706169 |
|
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [10-nitro-oleic acid results in increased expression of HSPB1 mRNA]; pyrazolanthrone inhibits the reaction [10-nitro-oleic acid results in increased expression of HSPB1 protein]; pyrazolanthrone inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of HSPB1 protein] |
CTD |
PMID:21457723 PMID:24140437 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Hspb8 |
heat shock protein family B (small) member 8 |
multiple interactions |
ISO |
pyrazolanthrone promotes the reaction [Ozone results in increased expression of HSPB8 mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185
|
|
G |
Ibsp |
integrin-binding sialoprotein |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Ketoglutaric Acids results in increased expression of IBSP protein] |
CTD |
PMID:31051157 |
|
NCBI chr14:5,439,825...5,452,570
Ensembl chr14:5,439,829...5,452,693
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of ICAM1 mRNA]; pyrazolanthrone inhibits the reaction [Zinc Oxide results in increased expression of ICAM1] |
CTD |
PMID:12832416 PMID:22166487 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [[Diclofenac co-treated with IFNG protein] results in increased phosphorylation of STAT1 protein]; pyrazolanthrone inhibits the reaction [Eosine I Bluish results in increased expression of IFNG mRNA] pyrazolanthrone inhibits the reaction [[Polysaccharides co-treated with IFNG protein] results in increased expression of TNF protein] [pyrazolanthrone co-treated with Manganese] inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased localization of RELA protein]; pyrazolanthrone inhibits the reaction [[Iodine co-treated with Dibutyl Phthalate] results in increased expression of IFNG protein]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; pyrazolanthrone inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; pyrazolanthrone inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]]; pyrazolanthrone results in decreased susceptibility to [IFNG protein co-treated with Lipopolysaccharides] |
CTD |
PMID:16307444 PMID:16488514 PMID:21295052 PMID:22440610 PMID:23831309 PMID:26609140 PMID:29385629 More...
|
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [[IGF1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [[IGF1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:17458902 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [sodium arsenite results in increased phosphorylation of IKBKB protein] |
CTD |
PMID:19616567 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Fungal Polysaccharides results in increased secretion of IL10 protein] |
CTD |
PMID:28235615 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [nickel sulfate results in increased secretion of IL12B protein] pyrazolanthrone promotes the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] |
CTD |
PMID:15778123 PMID:19101624 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased secretion of IL13 protein] |
CTD |
PMID:33075463 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [[Iodine co-treated with Dibutyl Phthalate] results in increased expression of IL17A protein] |
CTD |
PMID:29385629 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [[Lipopolysaccharides co-treated with irinotecan] results in increased expression of and results in increased secretion of IL18 protein] pyrazolanthrone inhibits the reaction [Benzo(a)pyrene results in increased secretion of IL18 protein]; pyrazolanthrone inhibits the reaction [Irinotecan results in increased expression of and results in increased secretion of IL18 protein]; pyrazolanthrone inhibits the reaction [Picryl Chloride results in increased expression of IL18 mRNA]; pyrazolanthrone inhibits the reaction [Picryl Chloride results in increased secretion of IL18 protein] |
CTD |
PMID:20381601 PMID:26431797 PMID:35777681 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of CXCL10 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of CXCL8 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of FGF2 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of GCH1 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of ICAM1 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of IL1A mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of IL1B mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of MMP1 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of MMP3 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of PTX3 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of SERPINB2 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of SOD2 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased secretion of CXCL8 protein]; pyrazolanthrone promotes the reaction [IL1A protein results in increased expression of BIRC2 mRNA]; pyrazolanthrone promotes the reaction [IL1A protein results in increased expression of CCL8 mRNA]; pyrazolanthrone promotes the reaction [IL1A protein results in increased expression of CXCL3 mRNA]; pyrazolanthrone promotes the reaction [IL1A protein results in increased expression of JUN mRNA]; pyrazolanthrone promotes the reaction [IL1A protein results in increased expression of SAA1 mRNA] pyrazolanthrone inhibits the reaction [Soot results in increased secretion of IL1A protein] |
CTD |
PMID:12832416 PMID:19782127 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
[Sulfasalazine co-treated with pyrazolanthrone] inhibits the reaction [IL1B protein results in decreased expression of DIO1 mRNA]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides co-treated with irinotecan] results in increased expression of and results in increased secretion of IL1B protein]; pyrazolanthrone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL1B mRNA]; pyrazolanthrone inhibits the reaction [APP protein results in increased expression of and results in increased cleavage of IL1B protein]; pyrazolanthrone inhibits the reaction [Benzo(a)pyrene results in increased secretion of IL1B protein]; pyrazolanthrone inhibits the reaction [beta Carotene promotes the reaction [Benzo(a)pyrene results in increased secretion of IL1B protein]]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of IL1B mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased activity of MMP12 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of JUN protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of CYP4F11 mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of F3 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of MMP12 mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of PAPPA mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of TGFB1 mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased secretion of FGF7 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased secretion of TGFB1 protein]; pyrazolanthrone inhibits the reaction [IL1B results in increased expression of CXCL8 protein]; pyrazolanthrone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL1B mRNA]; pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IL1B mRNA]; pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IL1B protein] IL1B protein inhibits the reaction [[Sulfasalazine co-treated with pyrazolanthrone] results in decreased expression of THRA mRNA]; IL1B protein inhibits the reaction [pyrazolanthrone results in increased expression of THRA mRNA alternative form]; pyrazolanthrone affects the reaction [Fungal Polysaccharides results in increased expression of IL1B mRNA]; pyrazolanthrone inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; pyrazolanthrone inhibits the reaction [sodium chromate(VI) results in increased expression of IL1B mRNA]; pyrazolanthrone inhibits the reaction [T-2 Toxin results in increased expression of IL1B mRNA] pyrazolanthrone inhibits the reaction [2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]]; pyrazolanthrone inhibits the reaction [7-Ala-angiotensin (1-7) inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]]; pyrazolanthrone inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased localization of RELA protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased expression of and results in increased secretion of IL1B protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of HRK mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of HRK protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [lead acetate results in increased expression of IL1B protein]; pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of IL1B mRNA]; pyrazolanthrone inhibits the reaction [Soot results in increased secretion of IL1B protein] |
CTD |
PMID:12832416 PMID:15019843 PMID:15677771 PMID:16359550 PMID:16365456 PMID:16614379 PMID:17641275 PMID:18982426 PMID:19626664 PMID:19782127 PMID:19812349 PMID:20712904 PMID:21295052 PMID:21430222 PMID:21447443 PMID:22547200 PMID:22687552 PMID:22727857 PMID:22728154 PMID:23535185 PMID:24781252 PMID:26218279 PMID:26431797 PMID:27174766 PMID:27302421 PMID:27556861 PMID:28004443 PMID:31199065 PMID:35172196 PMID:36775139 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
EXP ISO |
pyrazolanthrone inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 mRNA]; pyrazolanthrone inhibits the reaction [dinitrophenyl-bovine serum albumin results in increased expression of IL4 protein] pyrazolanthrone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased secretion of IL4 protein] |
CTD |
PMID:26003274 PMID:33075463 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased secretion of IL5 protein] |
CTD |
PMID:33075463 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [7-ketocholesterol results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [Acids results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [Acids results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [cobaltous chloride results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [doxifluridine results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [Fluorouracil results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; pyrazolanthrone inhibits the reaction [nickel sulfate results in increased expression of IL6 protein]; pyrazolanthrone inhibits the reaction [nickel sulfate results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [OSM protein results in increased expression of and results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of and results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [polyhexamethyleneguanidine results in increased expression of IL6 mRNA]; pyrazolanthrone promotes the reaction [cadmium acetate results in increased secretion of IL6 protein] pyrazolanthrone inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [di-n-butyltin results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [di-n-butyltin results in increased expression of IL6 protein]; pyrazolanthrone inhibits the reaction [Fungal Polysaccharides results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; pyrazolanthrone inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [perfluorooctane sulfonic acid results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [T-2 Toxin results in increased expression of IL6 mRNA]; pyrazolanthrone promotes the reaction [Arsenic Trioxide results in increased expression of IL6 mRNA]; pyrazolanthrone promotes the reaction [Ozone results in increased expression of IL6 mRNA] [pyrazolanthrone co-treated with Acrylamide] results in decreased expression of IL6 mRNA; pyrazolanthrone inhibits the reaction [[Iodine co-treated with Dibutyl Phthalate] results in increased expression of IL6 protein]; pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [lead acetate results in increased expression of IL6 protein]; pyrazolanthrone inhibits the reaction [Palmitic Acid results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of and results in increased secretion of IL6 protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of IL6 mRNA]; pyrazolanthrone inhibits the reaction [Soot results in increased secretion of IL6 protein] |
CTD |
PMID:12832416 PMID:17460151 PMID:18515973 PMID:19074641 PMID:19101624 PMID:19782127 PMID:20712904 PMID:21548952 PMID:22488045 PMID:22727857 PMID:22728154 PMID:23535185 PMID:24631921 PMID:25047101 PMID:25677194 PMID:26862037 PMID:27427241 PMID:28087833 PMID:28235615 PMID:28474156 PMID:29385629 PMID:29426002 PMID:29906494 PMID:30078834 PMID:30259999 PMID:35122928 PMID:35147423 PMID:35499276 PMID:36775139 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [bisphenol A inhibits the reaction [INS1 protein results in increased phosphorylation of INSR protein]]; pyrazolanthrone inhibits the reaction [bisphenol A inhibits the reaction [INS1 protein results in increased phosphorylation of MAPK1 protein]]; pyrazolanthrone inhibits the reaction [bisphenol A inhibits the reaction [INS1 protein results in increased phosphorylation of MAPK3 protein]]; pyrazolanthrone inhibits the reaction [bisphenol A inhibits the reaction [INS1 protein results in increased uptake of Glucose]] |
CTD |
PMID:24349194 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
EXP ISO |
pyrazolanthrone inhibits the reaction [Paroxetine affects the reaction [INS protein affects the phosphorylation of IRS1 protein]] pyrazolanthrone inhibits the reaction [GW8510 results in increased expression of INS2 mRNA] |
CTD |
PMID:17728140 PMID:22242153 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insr |
insulin receptor |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [bisphenol A inhibits the reaction [INS1 protein results in increased phosphorylation of INSR protein]]; pyrazolanthrone inhibits the reaction [bisphenol A results in decreased expression of INSR protein modified form] pyrazolanthrone inhibits the reaction [oleoylethanolamide affects the phosphorylation of and affects the activity of INSR protein] |
CTD |
PMID:19345745 PMID:24349194 PMID:29793316 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
EXP ISO |
pyrazolanthrone inhibits the reaction [Paroxetine affects the reaction [INS protein affects the phosphorylation of IRS1 protein]] pyrazolanthrone inhibits the reaction [bisphenol A results in increased expression of IRS1 protein modified form] |
CTD |
PMID:17728140 PMID:29793316 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Itga2b |
integrin subunit alpha 2b |
multiple interactions |
ISO |
pyrazolanthrone promotes the reaction [THPO protein results in increased expression of ITGA2B protein] |
CTD |
PMID:20523355 |
|
NCBI chr10:87,408,532...87,426,055
Ensembl chr10:87,408,536...87,426,168
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
pyrazolanthrone promotes the reaction [arsenic disulfide analog results in increased expression of ITGAM mRNA]; pyrazolanthrone promotes the reaction [arsenic disulfide analog results in increased expression of ITGAM protein] |
CTD |
PMID:18778786 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ITGB3 protein]; pyrazolanthrone promotes the reaction [THPO protein results in increased expression of ITGB3 protein] |
CTD |
PMID:20523355 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Jag1 |
jagged canonical Notch ligand 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of JAG1 mRNA] |
CTD |
PMID:21843347 |
|
NCBI chr 3:124,406,783...124,442,220
Ensembl chr 3:124,406,794...124,442,209
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases phosphorylation decreases expression increases degradation decreases activity |
ISO EXP |
[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one co-treated with 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole co-treated with pyrazolanthrone] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of JUN protein]; [pyrazolanthrone results in decreased phosphorylation of JUN protein] inhibits the reaction [JUN protein binds to TOP1 protein]; [U 0126 co-treated with pyrazolanthrone] inhibits the reaction [2-aminodiphenyl results in increased phosphorylation of and results in increased expression of JUN protein]; pyrazolanthrone inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of JUN protein modified form]; pyrazolanthrone inhibits the reaction [2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [2-aminodiphenyl results in increased expression of and results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [8-bromo-7-methoxychrysin results in increased expression of JUN protein]; pyrazolanthrone inhibits the reaction [[Disulfiram co-treated with Copper co-treated with Doxorubicin] results in increased phosphorylation of and results in increased expression of JUN protein]; pyrazolanthrone inhibits the reaction [[Ethacrynic Acid co-treated with Arsenic Trioxide] results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [[Quercetin co-treated with mibolerone] results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [[Sorafenib co-treated with Vitamin K 1] results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased expression of JUN protein]; pyrazolanthrone inhibits the reaction [Benzo(a)pyrene results in increased expression of JUN protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Cadmium results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Chloramphenicol results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Cisplatin results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [diethyl maleate results in increased expression of JUN protein modified form]; pyrazolanthrone inhibits the reaction [Estradiol results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Fenretinide results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [hydroquinone results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of and results in increased activity of JUN protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [Leflunomide results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Methyl Methanesulfonate results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [MIF protein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Morphine results in increased phosphorylation of and results in increased activity of JUN protein]; pyrazolanthrone inhibits the reaction [O(2)-(2,4-dinitrophenyl) 1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased activity of JUN protein]; pyrazolanthrone inhibits the reaction [Quercetin affects the localization of JUN protein]; pyrazolanthrone inhibits the reaction [Silicon Dioxide results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Simvastatin results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in decreased expression of JUN protein modified form]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased activity of JUN protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Sorafenib results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [Sorafenib results in increased expression of JUN protein]; pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of JUN protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Tretinoin results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Zinc Oxide affects the localization of JUN protein]; pyrazolanthrone inhibits the reaction [Zinc Oxide results in increased phosphorylation of and results in increased activity of JUN protein]; pyrazolanthrone promotes the reaction [IL1A protein results in increased expression of JUN mRNA] pyrazolanthrone inhibits the reaction [1-hydroxy-2-oxo-3,3-bis(2-aminoethyl)-1-triazene results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal results in increased activity of [JUN protein binds to JUN protein]]; pyrazolanthrone inhibits the reaction [[[cupric chloride results in increased abundance of Copper] co-treated with [zinc chloride results in increased abundance of Zinc]] results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [bisphenol A results in increased expression of and results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [bisphenol A results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [monobutyl phthalate results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Ozone results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [TNF protein promotes the reaction [diethyl maleate results in increased phosphorylation of JUN protein]]; pyrazolanthrone inhibits the reaction [TNF protein results in increased phosphorylation of JUN protein]; pyrazolanthrone promotes the reaction [[Cisplatin co-treated with TNF protein] results in increased phosphorylation of JUN protein] [cypermethrin co-treated with pyrazolanthrone] results in decreased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Acrolein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Amphetamine results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [cypermethrin results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Indolinone A results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [manganese chloride results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Norepinephrine results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased activity of JUN protein]; pyrazolanthrone inhibits the reaction [Patulin results in increased expression of JUN protein]; pyrazolanthrone inhibits the reaction [Phenylephrine results in increased expression of JUN mRNA]; pyrazolanthrone promotes the reaction [celastrol inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased phosphorylation of JUN protein]] pyrazolanthrone results in decreased expression of JUN protein pyrazolanthrone results in increased degradation of JUN protein pyrazolanthrone results in decreased activity of JUN protein |
CTD |
PMID:12169099 PMID:12393500 PMID:12663670 PMID:12774022 PMID:12832416 PMID:15019843 PMID:15028728 PMID:15034932 PMID:15194466 PMID:15196213 PMID:15252869 PMID:15322261 PMID:15342272 PMID:15677771 PMID:15838870 PMID:15850772 PMID:15923621 PMID:15930183 PMID:16041517 PMID:16061660 PMID:16166651 PMID:16322078 PMID:16337876 PMID:16357177 PMID:16407847 PMID:16872482 PMID:16932349 PMID:17125918 PMID:17460151 PMID:17950587 PMID:18021293 PMID:18593901 PMID:18633430 PMID:18982426 PMID:19002563 PMID:19225867 PMID:19292871 PMID:19418558 PMID:19768117 PMID:19812349 PMID:20148354 PMID:20301194 PMID:20338993 PMID:20632440 PMID:21062976 PMID:21165570 PMID:21911303 PMID:22003962 PMID:22020770 PMID:22166487 PMID:22288910 PMID:23082001 PMID:23103562 PMID:23219847 PMID:23791922 PMID:23836369 PMID:24111524 PMID:24469321 PMID:24967690 PMID:25200491 PMID:25237887 PMID:26209791 PMID:26514923 PMID:26630137 PMID:28087833 PMID:28474156 PMID:28697429 PMID:28988120 PMID:30133131 PMID:30261343 PMID:30709899 PMID:30768131 PMID:32738922 PMID:33677747 PMID:33959992 PMID:34794910 PMID:34896196 PMID:35172196 PMID:35512476 PMID:35689653 More...
|
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [2-tert-butylhydroquinone results in increased phosphorylation of JUND protein] |
CTD |
PMID:24830941 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Kcnb1 |
potassium voltage-gated channel subfamily B member 1 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Methamphetamine results in increased expression of KCNB1 protein] |
CTD |
PMID:29297590 |
|
NCBI chr 3:155,820,255...155,913,383
Ensembl chr 3:155,822,963...155,916,194
|
|
G |
Kcne4 |
potassium voltage-gated channel subfamily E regulatory subunit 4 |
multiple interactions |
ISO |
pyrazolanthrone promotes the reaction [Ozone results in increased expression of KCNE4 mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr 9:80,243,429...80,251,533
Ensembl chr 9:80,247,379...80,250,979
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [pachastrissamine analog promotes the reaction [KEAP1 protein binds to SQSTM1 protein]] |
CTD |
PMID:35123989 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Klf5 |
KLF transcription factor 5 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Ozone results in increased expression of KLF5 mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445
|
|
G |
Klf6 |
KLF transcription factor 6 |
decreases expression multiple interactions |
ISO |
pyrazolanthrone results in decreased expression of KLF6 mRNA Arachidonic Acid inhibits the reaction [pyrazolanthrone results in decreased expression of KLF6 mRNA]; pyrazolanthrone inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; pyrazolanthrone inhibits the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA] |
CTD |
PMID:22486562 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Klhl2 |
kelch-like family member 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Ozone results in increased expression of KLHL2 mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr16:24,860,744...24,973,348
Ensembl chr16:24,860,667...24,973,341
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of LDLR mRNA]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of LDLR protein] |
CTD |
PMID:22388943 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [LEP protein results in increased expression of CYP19A1 mRNA]; pyrazolanthrone inhibits the reaction [LEP protein results in increased expression of CYP19A1 protein] |
CTD |
PMID:28571770 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
affects response to substance |
ISO |
LEPR protein affects the susceptibility to pyrazolanthrone |
CTD |
PMID:22933112 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lpl |
lipoprotein lipase |
increases expression multiple interactions |
ISO |
pyrazolanthrone results in increased expression of LPL mRNA pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in decreased expression of LPL mRNA] |
CTD |
PMID:21873422 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Map1lc3a |
microtubule-associated protein 1 light chain 3 alpha |
decreases expression |
EXP |
SP600125 decreases expression of protein in oxygen-glucose deprived rat neuronal PC12 cells |
RGD |
PMID:27769861 |
RGD:329853763 |
NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [butein results in increased lipidation of MAP1LC3B protein]; pyrazolanthrone promotes the reaction [sodium arsenite results in increased expression of and results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:34861471 PMID:35130734 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [[MAP2K6 gene mutant form results in increased activity of MAP2K6 protein] which results in increased susceptibility to Tetradecanoylphorbol Acetate] |
CTD |
PMID:27278863 |
|
NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [[MAP3K1 gene mutant form results in increased activity of MAP3K1 protein] which results in increased susceptibility to Tetradecanoylphorbol Acetate]; pyrazolanthrone inhibits the reaction [MAP3K1 protein results in increased expression of ABCB1 mRNA] |
CTD |
PMID:15604272 PMID:27278863 |
|
NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463
|
|
G |
Map3k6 |
mitogen-activated protein kinase kinase kinase 6 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Ozone results in increased expression of MAP3K6 mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr 5:145,440,126...145,452,213
Ensembl chr 5:145,440,346...145,452,212
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [[IGF1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [bisphenol A inhibits the reaction [INS1 protein results in increased phosphorylation of MAPK1 protein]]; pyrazolanthrone inhibits the reaction [Diclofenac results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [honokiol results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK1 protein] [pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone promotes the reaction [manganese chloride results in increased phosphorylation of MAPK1 protein] pyrazolanthrone inhibits the reaction [etoxazole results in increased phosphorylation of MAPK1 protein]; pyrazolanthrone inhibits the reaction [flufenoxuron results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:15342272 PMID:17458902 PMID:19135517 PMID:21933187 PMID:22727857 PMID:24349194 PMID:26136938 PMID:26359795 PMID:26609140 PMID:28087833 PMID:30317802 PMID:33550458 PMID:33618463 PMID:33771252 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions increases expression decreases phosphorylation |
ISO EXP |
pyrazolanthrone inhibits the reaction [cinnamaldehyde results in increased phosphorylation of MAPK14 protein] pyrazolanthrone results in increased expression of MAPK14 protein pyrazolanthrone results in decreased phosphorylation of MAPK14 protein |
CTD |
PMID:15964311 PMID:16046226 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [[IGF1 protein co-treated with Estradiol] results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [bisphenol A inhibits the reaction [INS1 protein results in increased phosphorylation of MAPK3 protein]]; pyrazolanthrone inhibits the reaction [Diclofenac results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [honokiol results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK3 protein] [pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone promotes the reaction [manganese chloride results in increased phosphorylation of MAPK3 protein] [TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of MAPK3 mRNA; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of MAPK3 mRNA]; pyrazolanthrone inhibits the reaction [etoxazole results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [flufenoxuron results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15342272 PMID:17458902 PMID:19135517 PMID:21933187 PMID:22727857 PMID:24349194 PMID:26136938 PMID:26359795 PMID:26609140 PMID:28087833 PMID:30317802 PMID:30580027 PMID:33550458 PMID:33618463 PMID:33771252 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions decreases activity decreases phosphorylation increases expression decreases expression |
ISO EXP |
pyrazolanthrone inhibits the reaction [5-((4-methylphenyl)methylene)-2-(phenylamino)-4(5H)-thiazolone results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [8-bromo-7-methoxychrysin results in increased phosphorylation of and results in increased activity of MAPK8 protein]; pyrazolanthrone inhibits the reaction [[Clioquinol co-treated with Copper] results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [[Sirolimus co-treated with 7-hydroxystaurosporine] results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [arsenic trichloride results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Benzo(a)pyrene results in increased expression of MAPK8 protein]; pyrazolanthrone inhibits the reaction [benzyl isothiocyanate results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [cinnamaldehyde results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [cordycepin results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [diethyl maleate results in increased expression of MAPK8 protein modified form]; pyrazolanthrone inhibits the reaction [dracorhodin analog results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [glycine-extended gastrin 17 results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [LY 293111 results in increased expression of MAPK8 protein modified form]; pyrazolanthrone inhibits the reaction [nickel sulfate results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [pachastrissamine analog results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Plant Extracts results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [polyphyllin I results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Resveratrol results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [rhoifolin results in increased expression of and results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Silicon Dioxide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Silybin results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Sodium Selenite results in increased phosphorylation of and results in increased activity of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK8 protein]]; pyrazolanthrone inhibits the reaction [TNF protein results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone promotes the reaction [dehydrocrenatidine results in decreased phosphorylation of MAPK8 protein] pyrazolanthrone results in decreased activity of MAPK8 protein [pyrazolanthrone co-treated with 6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride] inhibits the reaction [Folic Acid results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone affects the reaction [TALDO1 gene mutant form promotes the reaction [Acetaminophen results in increased activity of and results in increased phosphorylation of MAPK8 protein]]; pyrazolanthrone inhibits the reaction [[[cupric chloride results in increased abundance of Copper] co-treated with [zinc chloride results in increased abundance of Zinc]] results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased activity of and results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased phosphorylation of and affects the activity of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Acrylamide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Cadmium results in increased phosphorylation of and results in increased activity of MAPK8 protein]; pyrazolanthrone inhibits the reaction [flufenoxuron results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Folic Acid results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased phosphorylation of and results in increased activity of MAPK8 protein]; pyrazolanthrone inhibits the reaction [pseudolaric acid B results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Tretinoin results in increased activity of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Triclosan results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone results in decreased phosphorylation of and results in decreased activity of MAPK8 protein [cypermethrin co-treated with pyrazolanthrone] results in decreased phosphorylation of MAPK8 protein; pyrazolanthrone inhibits the reaction [[Copper co-treated with pyrrolidine dithiocarbamic acid] results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [cypermethrin results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [nickel chloride results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Palmitic Acid results in increased expression of MAPK8 mRNA]; pyrazolanthrone inhibits the reaction [Palmitic Acid results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Paroxetine results in increased phosphorylation of and results in increased activity of MAPK8 protein]; pyrazolanthrone inhibits the reaction [pentaacetyl geniposide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Sertraline results in increased phosphorylation of and results in increased activity of MAPK8 protein] pyrazolanthrone results in decreased phosphorylation of MAPK8 protein pyrazolanthrone results in increased expression of MAPK8 protein SP600125 decreases expression of protein in oxygen-glucose deprived rat neuronal PC12 cells |
CTD RGD |
PMID:12534346 PMID:14610070 PMID:15322261 PMID:15767555 PMID:15831436 PMID:15964311 PMID:16041517 PMID:16046226 PMID:16151469 PMID:16374168 PMID:16442704 PMID:16648635 PMID:16687388 PMID:16777994 PMID:16864444 PMID:17185352 PMID:17651887 PMID:17728140 PMID:18347188 PMID:18412143 PMID:18495191 PMID:18506790 PMID:18728404 PMID:18840457 PMID:19038359 PMID:19135517 PMID:19436114 PMID:20206247 PMID:20534739 PMID:20632440 PMID:20678559 PMID:21048310 PMID:21112663 PMID:21219922 PMID:21626648 PMID:21843586 PMID:21933187 PMID:22085843 PMID:22696236 PMID:24833599 PMID:25531190 PMID:26385185 PMID:27174766 PMID:28099944 PMID:28474156 PMID:29906494 PMID:30259999 PMID:30261343 PMID:30768131 PMID:31176653 PMID:31348969 PMID:31421117 PMID:31447676 PMID:31587482 PMID:31734849 PMID:32574669 PMID:33075463 PMID:33771252 PMID:33959992 PMID:34076342 PMID:34160118 PMID:34794910 PMID:35123989 PMID:35172196 PMID:35383226 PMID:35512476 PMID:35689653 PMID:37244295 PMID:38372072 PMID:27769861 More...
|
RGD:329853763 |
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions decreases activity decreases phosphorylation |
ISO EXP |
pyrazolanthrone inhibits the reaction [5-((4-methylphenyl)methylene)-2-(phenylamino)-4(5H)-thiazolone results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [arsenic trichloride results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [diethyl maleate results in increased expression of MAPK9 protein modified form]; pyrazolanthrone inhibits the reaction [LY 293111 results in increased expression of MAPK9 protein modified form]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Plant Extracts results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [polyphyllin I results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Resveratrol results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [sanguinarine results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Silicon Dioxide results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Silybin results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Sodium Selenite results in increased phosphorylation of and results in increased activity of MAPK9 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone promotes the reaction [dehydrocrenatidine results in decreased phosphorylation of MAPK9 protein] pyrazolanthrone results in decreased activity of MAPK9 protein pyrazolanthrone inhibits the reaction [Acrylamide results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased phosphorylation of and results in increased activity of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Toluene 2,4-Diisocyanate results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Triclosan results in increased phosphorylation of MAPK9 protein] pyrazolanthrone inhibits the reaction [[Copper co-treated with pyrrolidine dithiocarbamic acid] results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [nickel chloride results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [pentaacetyl geniposide results in increased phosphorylation of MAPK9 protein] pyrazolanthrone results in decreased phosphorylation of MAPK9 protein |
CTD |
PMID:12534346 PMID:15322261 PMID:15831436 PMID:16151469 PMID:16687388 PMID:16777994 PMID:17651887 PMID:18347188 PMID:18412143 PMID:18728404 PMID:18840457 PMID:19038359 PMID:19135517 PMID:20206247 PMID:20678559 PMID:21843586 PMID:22085843 PMID:22696236 PMID:25531190 PMID:26385185 PMID:27174766 PMID:28474156 PMID:29906494 PMID:30261343 PMID:31348969 PMID:31421117 PMID:33075463 PMID:34076342 PMID:34160118 PMID:35689653 More...
|
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapkapk2 |
MAPK activated protein kinase 2 |
decreases activity |
EXP |
pyrazolanthrone results in decreased activity of MAPKAPK2 protein |
CTD |
PMID:15196213 |
|
NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [arsenic trioxide promotes the reaction [Ethacrynic Acid results in decreased expression of MCL1 protein]]; pyrazolanthrone promotes the reaction [usnic acid results in decreased expression of MCL1 protein] |
CTD |
PMID:23082001 PMID:25078063 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mcm2 |
minichromosome maintenance complex component 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [trichostatin A results in decreased expression of MCM2 protein] |
CTD |
PMID:23770000 |
|
NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847
|
|
G |
Mif |
macrophage migration inhibitory factor |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [MIF protein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [MIF protein results in increased phosphorylation of PRKCD protein] |
CTD |
PMID:16872482 |
|
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504 Ensembl chr 4:12,790,902...12,799,504
|
|
G |
Mir21 |
microRNA 21 |
affects expression multiple interactions |
ISO |
pyrazolanthrone affects the expression of MIR21 mRNA pyrazolanthrone affects the reaction [arsenic trichloride affects the expression of MIR21 mRNA] |
CTD |
PMID:24434654 |
|
NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
|
|
G |
Mir328 |
microRNA 328 |
increases expression |
ISO |
pyrazolanthrone results in increased expression of MIR328 mRNA |
CTD |
PMID:25605016 |
|
NCBI chr19:33,184,766...33,184,849
Ensembl chr19:33,184,766...33,184,849
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased expression of and results in increased activity of MMP1 protein]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of MMP1 mRNA]; pyrazolanthrone inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of and results in increased activity of MMP1 protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP1 protein] |
CTD |
PMID:12832416 PMID:20004183 PMID:24469321 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [IL1B protein results in increased activity of MMP12 protein]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of MMP12 mRNA] |
CTD |
PMID:16359550 |
|
NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Chloramphenicol results in increased expression of MMP13 mRNA]; pyrazolanthrone inhibits the reaction [S100A4 protein results in increased expression of MMP13 protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP13 protein] |
CTD |
PMID:16948116 PMID:20004183 PMID:20338993 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Acrolein results in increased expression of MMP14 mRNA] |
CTD |
PMID:19661247 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [mangostin analog results in decreased expression of MMP2 protein]; pyrazolanthrone inhibits the reaction [Resveratrol results in decreased expression of MMP2]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP2 protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 mRNA]; pyrazolanthrone inhibits the reaction [thymoquinone results in decreased expression of MMP2 protein]; pyrazolanthrone promotes the reaction [dehydrocrenatidine results in decreased expression of MMP2 protein]; pyrazolanthrone promotes the reaction [Resveratrol results in decreased expression of and results in decreased activity of MMP2 protein] pyrazolanthrone inhibits the reaction [Doxorubicin results in increased activity of MMP2 protein]; pyrazolanthrone inhibits the reaction [Doxorubicin results in increased expression of MMP2 mRNA] pyrazolanthrone inhibits the reaction [Particulate Matter results in increased methylation of MMP2 promoter] |
CTD |
PMID:16213474 PMID:20599481 PMID:22355787 PMID:24841706 PMID:25605016 PMID:27060453 PMID:28722351 PMID:34076342 More...
|
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased expression of MMP3 mRNA]; pyrazolanthrone inhibits the reaction [Citrinin results in increased expression of MMP3 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of MMP3 mRNA]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP3 protein] |
CTD |
PMID:12832416 PMID:16778083 PMID:19361540 PMID:20004183 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases activity |
ISO EXP |
[kahweol acetate co-treated with pyrazolanthrone] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of and results in increased activity of MMP9 protein]; pyrazolanthrone affects the reaction [TNF protein results in increased expression of MMP9 protein]; pyrazolanthrone inhibits the reaction [Cadmium results in increased expression of MMP9 mRNA]; pyrazolanthrone inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased expression of MMP9 mRNA]; pyrazolanthrone inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased secretion of MMP9 protein]; pyrazolanthrone inhibits the reaction [hydroquinone results in increased secretion of MMP9 protein]; pyrazolanthrone inhibits the reaction [mangostin analog results in decreased expression of MMP9 protein]; pyrazolanthrone inhibits the reaction [Resveratrol results in decreased expression of MMP9]; pyrazolanthrone inhibits the reaction [tetrabromobisphenol A results in increased expression of MMP9 mRNA]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP9 protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 mRNA]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP9 protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of and results in increased activity of MMP9 protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]; pyrazolanthrone inhibits the reaction [thymoquinone results in decreased expression of MMP9 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of and results in increased activity of MMP9 protein]; pyrazolanthrone promotes the reaction [ovatodiolide results in decreased activity of MMP9 protein] pyrazolanthrone results in decreased activity of MMP9 protein pyrazolanthrone inhibits the reaction [RELA protein binds to MMP9 promoter]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of MMP9 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; pyrazolanthrone promotes the reaction [Doxorubicin results in increased expression of MMP9 mRNA] |
CTD |
PMID:16213474 PMID:19447859 PMID:20152819 PMID:21354279 PMID:22033475 PMID:22705379 PMID:22926441 PMID:23774252 PMID:24841706 PMID:25200491 PMID:26514923 PMID:26807887 PMID:27060453 PMID:28722351 PMID:30133131 PMID:30590137 PMID:30766661 More...
|
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Ozone results in increased expression of MT1 mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049 Ensembl chr X:10,826,032...10,827,049
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [EGF protein results in increased secretion of MUC5AC protein]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased expression of MUC5AC mRNA]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of MUC5AC mRNA]; pyrazolanthrone inhibits the reaction [polyhexamethyleneguanidine results in increased expression of MUC5AC mRNA]; pyrazolanthrone inhibits the reaction [polyhexamethyleneguanidine results in increased expression of MUC5AC protein]; pyrazolanthrone inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MUC5AC mRNA]; pyrazolanthrone inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MUC5AC protein]; pyrazolanthrone promotes the reaction [[Smoke results in increased abundance of Particulate Matter] which results in increased expression of MUC5AC mRNA] |
CTD |
PMID:21544845 PMID:22766066 PMID:25177032 PMID:30935901 PMID:31944254 PMID:34167450 More...
|
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression multiple interactions |
ISO EXP |
pyrazolanthrone results in increased expression of MYC protein MYC affects the reaction [pyrazolanthrone results in increased expression of BAX protein]; MYC affects the reaction [pyrazolanthrone results in increased expression of MYC protein]; MYC affects the reaction [pyrazolanthrone results in increased expression of TP53 protein] pyrazolanthrone inhibits the reaction [Diethylnitrosamine results in increased expression of MYC protein] |
CTD |
PMID:15034932 PMID:19418558 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myh2 |
myosin heavy chain 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Ozone results in increased expression of MYH2 mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr10:51,856,738...51,883,236
Ensembl chr10:51,856,738...51,883,236
|
|
G |
Myh6 |
myosin heavy chain 6 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in decreased expression of MYH6 mRNA] |
CTD |
PMID:21873422 |
|
NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in decreased expression of MYH7 mRNA] |
CTD |
PMID:21873422 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Glucose results in increased expression of NCF1 protein] |
CTD |
PMID:22245600 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions decreases expression |
ISO EXP |
pyrazolanthrone inhibits the reaction [3-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid results in increased activity of NFE2L2 protein]; pyrazolanthrone inhibits the reaction [3-O-caffeoyl-1-methylquinic acid affects the localization of NFE2L2 protein]; pyrazolanthrone inhibits the reaction [[3-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein] pyrazolanthrone results in decreased expression of NFE2L2 protein pyrazolanthrone inhibits the reaction [Acrylamide results in increased expression of NFE2L2 protein]; pyrazolanthrone inhibits the reaction [aureusidin affects the localization of NFE2L2 protein]; pyrazolanthrone inhibits the reaction [Chitosan analog inhibits the reaction [Doxorubicin affects the localization of NFE2L2 protein]]; pyrazolanthrone inhibits the reaction [Curcumin affects the localization of NFE2L2 protein]; pyrazolanthrone inhibits the reaction [diphenylarsinic acid results in increased expression of NFE2L2 protein] pyrazolanthrone inhibits the reaction [[Plant Extracts co-treated with Ethanol] results in increased expression of and affects the localization of NFE2L2 protein]; pyrazolanthrone inhibits the reaction [Triclosan results in increased expression of NFE2L2 protein] |
CTD |
PMID:16631525 PMID:17640564 PMID:23535287 PMID:25449124 PMID:25649257 PMID:28087833 PMID:29426002 PMID:30928397 PMID:31790703 PMID:34160118 More...
|
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO EXP |
pyrazolanthrone affects the reaction [sodium arsenite affects the expression of NFKB1 protein]; pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Lipopolysaccharides results in increased localization of NFKB1 protein]]; pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Nitroprusside results in increased localization of NFKB1 protein]]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Lipopolysaccharides results in increased localization of NFKB1 protein]]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased localization of NFKB1 protein]] pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Lipopolysaccharides results in increased localization of NFKB1 protein]]; pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Nitroprusside results in increased localization of NFKB1 protein]]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Lipopolysaccharides results in increased localization of NFKB1 protein]]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased localization of NFKB1 protein]]; pyrazolanthrone inhibits the reaction [sodium chromate(VI) results in increased phosphorylation of NFKB1 protein] pyrazolanthrone inhibits the reaction [Palmitic Acid results in increased expression of NFKB1 mRNA] |
CTD |
PMID:18507870 PMID:22547200 PMID:29528074 PMID:30259999 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [1,2,5,8-tetrahydroxy anthraquinone results in increased expression of NFKBIA protein]; pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased phosphorylation of NFKBIA protein]] pyrazolanthrone inhibits the reaction [Glucose results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:18507870 PMID:22245600 PMID:33030807 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [Edaravone results in increased expression of NGF mRNA]; pyrazolanthrone inhibits the reaction [Edaravone results in increased expression of NGF protein] pyrazolanthrone inhibits the reaction [pentaacetyl geniposide results in increased expression of NGF mRNA]; pyrazolanthrone inhibits the reaction [pentaacetyl geniposide results in increased expression of NGF protein] |
CTD |
PMID:17651887 PMID:19954754 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Ngfr |
nerve growth factor receptor |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [pentaacetyl geniposide results in increased expression of NGFR mRNA]; pyrazolanthrone inhibits the reaction [pentaacetyl geniposide results in increased expression of NGFR protein] |
CTD |
PMID:17651887 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of NLRP3 protein]; pyrazolanthrone inhibits the reaction [APP protein results in increased expression of NLRP3 protein] pyrazolanthrone inhibits the reaction [Palmitic Acid results in increased expression of NLRP3 mRNA] |
CTD |
PMID:28004443 PMID:30259999 PMID:34510229 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of NOS2 protein] pyrazolanthrone inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of NOS2 mRNA]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of NOS2 protein]; pyrazolanthrone inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; pyrazolanthrone inhibits the reaction [Humic Substances results in increased expression of NOS2 mRNA]; pyrazolanthrone inhibits the reaction [Humic Substances results in increased expression of NOS2 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; pyrazolanthrone inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]; pyrazolanthrone inhibits the reaction [Manganese results in increased expression of NOS2 mRNA]; pyrazolanthrone inhibits the reaction [Manganese results in increased expression of NOS2 protein]; pyrazolanthrone inhibits the reaction [Phosgene results in increased expression of NOS2 protein]; pyrazolanthrone inhibits the reaction [sodium chromate(VI) results in increased expression of NOS2 protein]; pyrazolanthrone inhibits the reaction [zinc protoporphyrin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; pyrazolanthrone inhibits the reaction [zinc protoporphyrin inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]]; pyrazolanthrone inhibits the reaction [zinc protoporphyrin inhibits the reaction [Peptidoglycan results in increased expression of NOS2 protein]] pyrazolanthrone inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; pyrazolanthrone inhibits the reaction [Palmitic Acid results in increased expression of NOS2 mRNA] |
CTD |
PMID:16417967 PMID:16488514 PMID:17570326 PMID:18507870 PMID:19376148 PMID:19497418 PMID:20004183 PMID:20423716 PMID:20712904 PMID:21818760 PMID:22227475 PMID:22547200 PMID:23268108 PMID:23500011 PMID:23727179 PMID:23735482 PMID:24239652 PMID:26218279 PMID:30259999 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Doxorubicin results in increased expression of NOX1 mRNA] |
CTD |
PMID:16213474 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of NPPB mRNA] |
CTD |
PMID:21873422 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Npy |
neuropeptide Y |
multiple interactions |
ISO |
pyrazolanthrone affects the reaction [bisphenol A affects the expression of NPY mRNA] |
CTD |
PMID:32960947 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [Copper results in increased expression of NQO1 mRNA]; pyrazolanthrone inhibits the reaction [Copper results in increased expression of NQO1 protein]; pyrazolanthrone inhibits the reaction [Lead results in increased expression of NQO1 mRNA]; pyrazolanthrone inhibits the reaction [Lead results in increased expression of NQO1 protein]; pyrazolanthrone inhibits the reaction [Mercury results in increased expression of NQO1 mRNA]; pyrazolanthrone inhibits the reaction [Mercury results in increased expression of NQO1 protein] pyrazolanthrone inhibits the reaction [Acrylamide results in increased expression of NQO1 mRNA] pyrazolanthrone inhibits the reaction [pachastrissamine analog affects the expression of NQO1 protein] |
CTD |
PMID:18752316 PMID:29426002 PMID:35123989 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Fenofibrate results in increased expression of NR0B2 mRNA] |
CTD |
PMID:19593819 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases expression |
ISO |
pyrazolanthrone results in increased expression of NR1H3 mRNA |
CTD |
PMID:19883121 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [NR1H4 gene mutant form promotes the reaction [Taurocholic Acid results in increased expression of CCL2 mRNA]] |
CTD |
PMID:28505368 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Valproic Acid inhibits the reaction [Corticosterone results in increased activity of NR3C1 protein]] |
CTD |
PMID:15249158 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
pyrazolanthrone promotes the reaction [Ozone results in increased expression of NR4A1 mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Optn |
optineurin |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of OPTN protein] |
CTD |
PMID:28776281 |
|
NCBI chr17:73,209,572...73,260,251
Ensembl chr17:73,209,575...73,260,251
|
|
G |
Osm |
oncostatin M |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [OSM protein results in increased expression of and results in increased secretion of IL6 protein] |
CTD |
PMID:21548952 |
|
NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313
|
|
G |
Ostm1 |
osteoclastogenesis associated transmembrane protein 1 |
multiple interactions |
ISO |
[crocin co-treated with pyrazolanthrone co-treated with TNFSF11 protein] results in decreased expression of OSTM1 mRNA; [TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of OSTM1 mRNA; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of OSTM1 mRNA] |
CTD |
PMID:30580027 |
|
NCBI chr20:46,071,657...46,187,049
Ensembl chr20:46,153,075...46,187,023
|
|
G |
Pappa |
pappalysin |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of PAPPA mRNA] |
CTD |
PMID:24781252 |
|
NCBI chr 5:78,497,660...78,735,873
Ensembl chr 5:78,498,300...78,730,666
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [1,4-naphthoquinone analog results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [3-oxo-29-noroleana-1,9(11),12-trien-2,20-dicarbonitrile results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [[Arsenic Trioxide co-treated with Ethacrynic Acid] results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [[cholix toxin, Vibrio cholerae co-treated with TNF protein] results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [[Sulindac co-treated with Arsenic Trioxide] results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [coronarin D results in increased expression of PARP1 protein modified form]; pyrazolanthrone inhibits the reaction [dehydroxymethylepoxyquinomicin results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [Docetaxel results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [Fenretinide results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [isoliensinine results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [licochalcone B results in increased expression of PARP1 protein]; pyrazolanthrone inhibits the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [LY 293111 results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [morusin results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [polyphyllin I results in increased expression of PARP1 protein modified form]; pyrazolanthrone inhibits the reaction [Quercetin results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]; pyrazolanthrone promotes the reaction [dihydromyricetin results in increased cleavage of PARP1 protein]; pyrazolanthrone promotes the reaction [pachastrissamine analog results in increased cleavage of PARP1 protein]; pyrazolanthrone promotes the reaction [picrasidine I results in increased expression of PARP1 protein modified form]; pyrazolanthrone results in increased susceptibility to [[TNFSF10 protein co-treated with kahweol acetate] results in increased cleavage of PARP1 protein] pyrazolanthrone inhibits the reaction [3-dinitrobenzene results in increased cleavage of PARP1 protein] pyrazolanthrone inhibits the reaction [[sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate] results in increased expression of PARP1 protein]; pyrazolanthrone inhibits the reaction [bakuchiol results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [cadmium acetate results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [nickel chloride results in increased cleavage of PARP1 protein] |
CTD |
PMID:14724571 PMID:15501958 PMID:16151469 PMID:16328441 PMID:16407847 PMID:17292878 PMID:18281123 PMID:19477251 PMID:19777565 PMID:20403343 PMID:21165570 PMID:21843586 PMID:23082001 PMID:23405080 PMID:24036456 PMID:24577723 PMID:25043952 PMID:25446857 PMID:25939952 PMID:26219228 PMID:27539140 PMID:28087840 PMID:28283887 PMID:29968959 PMID:30871965 PMID:31421117 PMID:33035517 PMID:34165247 PMID:34894061 PMID:35123989 PMID:35948134 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions decreases expression |
EXP ISO |
pyrazolanthrone inhibits the reaction [Diethylnitrosamine results in increased expression of PCNA protein] pyrazolanthrone results in decreased expression of PCNA protein |
CTD |
PMID:18593901 PMID:19418558 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
decreases expression |
EXP |
pyrazolanthrone results in decreased expression of PDGFRB mRNA; pyrazolanthrone results in decreased expression of PDGFRB protein |
CTD |
PMID:18332871 |
|
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Ozone results in increased expression of PDK4 mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Plat |
plasminogen activator, tissue type |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Valproic Acid results in increased activity of PLAT protein] |
CTD |
PMID:23378038 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [TNF protein results in increased activity of PLAU protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of PLAU protein]; pyrazolanthrone promotes the reaction [resveratrol results in decreased expression of PLAU protein] |
CTD |
PMID:19874453 PMID:23437203 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Nicotine results in increased expression of PLAUR mRNA] |
CTD |
PMID:22261521 |
|
NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595
|
|
G |
Plcb1 |
phospholipase C beta 1 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA] |
CTD |
PMID:19225867 |
|
NCBI chr 3:122,059,988...122,772,896
Ensembl chr 3:122,060,031...122,772,869
|
|
G |
Plcb3 |
phospholipase C beta 3 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA] |
CTD |
PMID:19225867 |
|
NCBI chr 1:204,143,257...204,160,384
Ensembl chr 1:204,144,956...204,160,228
|
|
G |
Plcd1 |
phospholipase C, delta 1 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA] |
CTD |
PMID:19225867 |
|
NCBI chr 8:118,795,196...118,818,186
Ensembl chr 8:118,795,201...118,818,186
|
|
G |
Plin3 |
perilipin 3 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [CpG ODN 1826 results in increased expression of PLIN3 mRNA] |
CTD |
PMID:20628022 |
|
NCBI chr 9:1,111,178...1,123,057
Ensembl chr 9:1,102,366...1,123,147
|
|
G |
Plxna2 |
plexin A2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Ozone results in increased expression of PLXNA2 mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr13:106,163,103...106,358,979
Ensembl chr13:106,163,103...106,358,979
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Chenodeoxycholic Acid results in decreased expression of PON1 mRNA]; pyrazolanthrone inhibits the reaction [FGF19 protein results in decreased expression of PON1 mRNA]; pyrazolanthrone inhibits the reaction [GW 4064 results in decreased expression of PON1 mRNA] |
CTD |
PMID:16269825 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Pon2 |
paraoxonase 2 |
decreases expression |
ISO |
pyrazolanthrone results in decreased expression of PON2 protein |
CTD |
PMID:15544923 |
|
NCBI chr 4:33,389,702...33,425,186
Ensembl chr 4:33,389,714...33,425,248
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions increases expression |
ISO |
pyrazolanthrone inhibits the reaction [TNF protein results in decreased expression of PPARA mRNA] pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in decreased expression of PPARA mRNA] pyrazolanthrone results in increased expression of PPARA mRNA |
CTD |
PMID:19883121 PMID:21873422 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Indomethacin results in increased expression of PPARD protein] |
CTD |
PMID:17341418 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression multiple interactions |
EXP |
pyrazolanthrone results in increased expression of PPARG mRNA; pyrazolanthrone results in increased expression of PPARG protein pyrazolanthrone inhibits the reaction [[sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate] results in increased expression of PPARG protein] |
CTD |
PMID:17372590 PMID:28283887 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression multiple interactions |
ISO |
pyrazolanthrone results in increased expression of PPARGC1A mRNA 6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride affects the reaction [pyrazolanthrone affects the reaction [[TGFB1 protein co-treated with TNF protein] affects the expression of PPARGC1A protein]]; 6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride promotes the reaction [pyrazolanthrone inhibits the reaction [Folic Acid results in decreased expression of PPARGC1A protein]]; pyrazolanthrone affects the reaction [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride affects the reaction [[TGFB1 protein co-treated with TNF protein] affects the expression of PPARGC1A protein]]; pyrazolanthrone affects the reaction [[TGFB1 protein co-treated with TNF protein] affects the expression of PPARGC1A protein]; pyrazolanthrone inhibits the reaction [Folic Acid results in decreased expression of PPARGC1A protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in decreased expression of PPARGC1A mRNA]; pyrazolanthrone promotes the reaction [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride inhibits the reaction [Folic Acid results in decreased expression of PPARGC1A protein]] |
CTD |
PMID:21873422 PMID:31447676 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prf1 |
perforin 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [resveratrol results in increased expression of PRF1 protein] |
CTD |
PMID:20082299 |
|
NCBI chr20:29,246,202...29,251,712
Ensembl chr20:29,246,202...29,251,701
|
|
G |
Prkcd |
protein kinase C, delta |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [MIF protein results in increased phosphorylation of PRKCD protein] |
CTD |
PMID:16872482 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Procr |
protein C receptor |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased cleavage of PROCR protein] |
CTD |
PMID:24632454 |
|
NCBI chr 3:144,254,596...144,258,863
Ensembl chr 3:144,254,380...144,258,903
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Ozone results in increased expression of PSAT1 mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [arsenic trioxide results in increased expression of PTEN protein] |
CTD |
PMID:20534739 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgds |
prostaglandin D2 synthase |
multiple interactions |
ISO |
pyrazolanthrone affects the reaction [2-chloroethyl ethyl sulfide results in increased expression of PTGDS mRNA] |
CTD |
PMID:20382172 |
|
NCBI chr 3:8,281,899...8,284,833
Ensembl chr 3:8,281,899...8,284,833
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; pyrazolanthrone inhibits the reaction [Aflatoxin B1 results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [Chlorpyrifos results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [Homocysteine results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [VEGFA protein results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [VEGFA protein results in increased expression of PTGS2 protein]; pyrazolanthrone promotes the reaction [Sodium Fluoride results in increased expression of PTGS2 protein]; pyrazolanthrone promotes the reaction [U 0126 inhibits the reaction [2-aminodiphenyl results in increased expression of PTGS2 protein]] pyrazolanthrone inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; pyrazolanthrone inhibits the reaction [arsenite results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [Endosulfan results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [Humic Substances results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [Humic Substances results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [lipoteichoic acid results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [Phosgene results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [sodium chromate(VI) results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [T-2 Toxin results in increased expression of PTGS2 mRNA]; pyrazolanthrone promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Sodium Selenite inhibits the reaction [pyrazolanthrone promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]] pyrazolanthrone inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [lead acetate results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [manganese chloride results in increased expression of PTGS2 protein]; pyrazolanthrone inhibits the reaction [Serotonin results in increased expression of PTGS2 mRNA] |
CTD |
PMID:12832416 PMID:17084486 PMID:18481333 PMID:18507870 PMID:18596194 PMID:18840457 PMID:19376214 PMID:19808956 PMID:20004183 PMID:21262218 PMID:21818760 PMID:21911040 PMID:22288910 PMID:22547200 PMID:22728154 PMID:22767315 PMID:23268108 PMID:23376440 PMID:23416140 PMID:23500011 PMID:23727179 PMID:23735482 PMID:24239652 PMID:24967690 PMID:25199686 PMID:25888188 PMID:26218279 PMID:27818125 PMID:36775139 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptx3 |
pentraxin 3 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of PTX3 mRNA] |
CTD |
PMID:12832416 |
|
NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323
|
|
G |
Rad51 |
RAD51 recombinase |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Prodigiosin results in decreased expression of RAD51 mRNA] |
CTD |
PMID:22579953 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Rapgef4 |
Rap guanine nucleotide exchange factor 4 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Ozone results in increased expression of RAPGEF4 mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr 3:56,809,388...57,101,332
Ensembl chr 3:56,809,270...57,102,316
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Calcitriol results in increased expression of RB1 mRNA]; pyrazolanthrone inhibits the reaction [Calcitriol results in increased expression of RB1 protein] |
CTD |
PMID:14729647 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Reg3g |
regenerating family member 3 gamma |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Ozone results in increased expression of REG3G mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr 4:110,922,805...110,927,803
Ensembl chr 4:110,924,168...110,926,723
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases expression |
ISO EXP |
pyrazolanthrone affects the reaction [sodium arsenite affects the expression of RELA protein]; pyrazolanthrone inhibits the reaction [Acids results in increased activity of RELA protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in decreased activity of RELA protein]; pyrazolanthrone inhibits the reaction [arsenite results in increased phosphorylation of RELA protein]; pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]]; pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Nitroprusside results in increased localization of RELA protein]]; pyrazolanthrone inhibits the reaction [Homocysteine results in increased activity of RELA protein]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased localization of RELA protein]]; pyrazolanthrone inhibits the reaction [Paraquat results in increased activity of RELA protein]; pyrazolanthrone inhibits the reaction [sodium arsenite affects the localization of RELA protein]; pyrazolanthrone inhibits the reaction [Sodium Fluoride affects the localization of RELA protein]; pyrazolanthrone inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of RELA protein] pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]]; pyrazolanthrone inhibits the reaction [Bee Venoms inhibits the reaction [Nitroprusside results in increased localization of RELA protein]]; pyrazolanthrone inhibits the reaction [Cisplatin inhibits the reaction [TNF protein affects the localization of RELA protein]]; pyrazolanthrone inhibits the reaction [Cyclosporine affects the localization of RELA protein]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Lipopolysaccharides results in increased localization of RELA protein]]; pyrazolanthrone inhibits the reaction [Melitten inhibits the reaction [Nitroprusside results in increased localization of RELA protein]]; pyrazolanthrone inhibits the reaction [perfluorooctane sulfonic acid results in increased phosphorylation of RELA protein]; pyrazolanthrone inhibits the reaction [sodium chromate(VI) results in increased phosphorylation of RELA protein] pyrazolanthrone inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased localization of RELA protein]; pyrazolanthrone inhibits the reaction [Acrylamide results in increased expression of RELA protein]; pyrazolanthrone inhibits the reaction [RELA protein binds to MMP9 promoter]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased phosphorylation of RELA protein]; pyrazolanthrone inhibits the reaction [TNF protein affects the localization of RELA protein] pyrazolanthrone results in decreased expression of RELA protein |
CTD |
PMID:18507870 PMID:19074641 PMID:19616567 PMID:20534739 PMID:21295052 PMID:22547200 PMID:22706169 PMID:23103562 PMID:23774252 PMID:23958496 PMID:25540590 PMID:25677194 PMID:25888188 PMID:28474156 PMID:29426002 PMID:29528074 PMID:30133131 PMID:36343453 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Riox2 |
ribosomal oxygenase 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [arsenic trichloride results in increased expression of RIOX2 mRNA]; pyrazolanthrone inhibits the reaction [arsenic trichloride results in increased phosphorylation of RIOX2 protein] |
CTD |
PMID:24434654 |
|
NCBI chr11:40,861,365...40,884,782
Ensembl chr11:40,860,774...40,884,574
|
|
G |
Robo1 |
roundabout guidance receptor 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [JZL 184 affects the localization of and affects the expression of ROBO1 protein] |
CTD |
PMID:25030704 |
|
NCBI chr11:10,580,863...11,621,675
Ensembl chr11:10,580,908...11,620,203
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions decreases activity |
ISO |
pyrazolanthrone affects the reaction [flufenoxuron results in decreased phosphorylation of RPS6KB1 protein]; pyrazolanthrone inhibits the reaction [arsenite results in decreased phosphorylation of RPS6KB1 protein]; pyrazolanthrone inhibits the reaction [Ketoglutaric Acids results in increased phosphorylation of RPS6KB1 protein] pyrazolanthrone results in decreased activity of RPS6KB1 protein |
CTD |
PMID:12534346 PMID:20589738 PMID:31051157 PMID:33771252 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
EXP ISO |
[pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased expression of RUNX2 mRNA] pyrazolanthrone inhibits the reaction [Ethanol results in increased activity of RUNX2 protein] |
CTD |
PMID:26136938 PMID:32198086 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Anisomycin results in increased phosphorylation of RXRA protein] pyrazolanthrone inhibits the reaction [arsenic trioxide results in increased phosphorylation of RXRA protein] |
CTD |
PMID:16038797 PMID:16184197 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
S100a4 |
S100 calcium-binding protein A4 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [S100A4 protein results in increased expression of MMP13 protein] |
CTD |
PMID:16948116 |
|
NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [FGF7 protein results in increased expression of SCD protein] |
CTD |
PMID:16162944 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Serpina7 |
serpin family A member 7 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [[Iodine co-treated with Dibutyl Phthalate] results in increased expression of SERPINA7 protein] |
CTD |
PMID:29385629 |
|
NCBI chr X:102,663,242...102,722,319
Ensembl chr X:102,663,405...102,669,040
|
|
G |
Serpinb2 |
serpin family B member 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of SERPINB2 mRNA] |
CTD |
PMID:12832416 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [Catechin results in decreased expression of SERPINE1 mRNA]; pyrazolanthrone inhibits the reaction [Quercetin results in decreased expression of SERPINE1 mRNA] pyrazolanthrone inhibits the reaction [Valproic Acid results in decreased activity of and results in decreased secretion of SERPINE1 protein] |
CTD |
PMID:17379280 PMID:23378038 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sftpa1 |
surfactant protein A1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Silicon Dioxide results in decreased expression of SFTPA1 protein] |
CTD |
PMID:35689653 |
|
NCBI chr16:17,008,180...17,011,686
Ensembl chr16:17,008,180...17,011,685
|
|
G |
Sftpb |
surfactant protein B |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Silicon Dioxide results in decreased expression of SFTPB protein] |
CTD |
PMID:35689653 |
|
NCBI chr 4:104,359,303...104,368,439
Ensembl chr 4:104,359,396...104,368,436
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
decreases activity |
ISO |
pyrazolanthrone results in decreased activity of SGK1 protein |
CTD |
PMID:12534346 |
|
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
|
|
G |
Shc1 |
SHC adaptor protein 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [diallyl trisulfide results in increased phosphorylation of SHC1 protein] |
CTD |
PMID:21616139 PMID:22020565 |
|
NCBI chr 2:174,837,937...174,849,538
Ensembl chr 2:174,837,930...174,849,536
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP ISO |
pyrazolanthrone inhibits the reaction [cobaltous chloride results in increased expression of SIRT1 protein] pyrazolanthrone inhibits the reaction [Silicon Dioxide promotes the reaction [Cycloheximide results in decreased expression of SIRT1 protein]]; pyrazolanthrone inhibits the reaction [Silicon Dioxide results in decreased expression of SIRT1 protein] |
CTD |
PMID:22669716 PMID:31082419 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc18a2 |
solute carrier family 18 member A2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Rotenone results in decreased activity of SLC18A2 protein] |
CTD |
PMID:25496994 |
|
NCBI chr 1:258,413,748...258,449,143
Ensembl chr 1:258,413,959...258,448,325
|
|
G |
Slc27a1 |
solute carrier family 27 member 1 |
multiple interactions increases expression |
ISO |
pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in decreased expression of SLC27A1 mRNA] pyrazolanthrone results in increased expression of SLC27A1 mRNA |
CTD |
PMID:21873422 |
|
NCBI chr16:18,278,984...18,300,173
Ensembl chr16:18,278,984...18,296,063
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
EXP ISO |
pyrazolanthrone inhibits the reaction [Diethylnitrosamine affects the phosphorylation of SMAD3 protein] [pyrazolanthrone co-treated with 6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride] inhibits the reaction [Folic Acid results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:19418558 PMID:31447676 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]; pyrazolanthrone inhibits the reaction [thymoquinone results in decreased expression of SNAI1 protein] |
CTD |
PMID:27060453 PMID:33396024 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 mRNA]; pyrazolanthrone inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein] |
CTD |
PMID:33396024 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Acetaminophen results in decreased activity of SOD1 protein] |
CTD |
PMID:33959992 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [BDNF protein results in increased expression of SOD2 protein]; pyrazolanthrone inhibits the reaction [IL1A protein results in increased expression of SOD2 mRNA] |
CTD |
PMID:12832416 PMID:22261313 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sorbs3 |
sorbin and SH3 domain containing 3 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [sodium arsenite promotes the reaction [CPEB4 protein binds to SORBS3 protein]] |
CTD |
PMID:25237887 |
|
NCBI chr15:45,252,921...45,284,758
Ensembl chr15:45,253,379...45,284,758
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of SOX2 protein] |
CTD |
PMID:23219847 |
|
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
multiple interactions |
ISO |
pyrazolanthrone promotes the reaction [resveratrol results in increased expression of SOX9] |
CTD |
PMID:24841706 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased phosphorylation of SP1 protein] [cypermethrin co-treated with pyrazolanthrone] results in decreased phosphorylation of SP1 protein |
CTD |
PMID:26385185 PMID:34794910 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
EXP ISO |
pyrazolanthrone inhibits the reaction [FGF1 protein results in increased expression of SPP1 mRNA] pyrazolanthrone inhibits the reaction [Ketoglutaric Acids results in increased expression of SPP1 protein] |
CTD |
PMID:15121739 PMID:31051157 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Sprr2a |
small proline rich protein 2A |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Ozone results in increased expression of SPRR2A mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr 2:177,815,964...177,816,236
Ensembl chr 2:177,815,964...177,816,236
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions increases expression decreases expression |
ISO EXP |
pyrazolanthrone affects the reaction [sodium arsenite affects the expression of SQSTM1 protein]; pyrazolanthrone inhibits the reaction [morusin results in decreased expression of SQSTM1 protein]; pyrazolanthrone inhibits the reaction [pachastrissamine analog promotes the reaction [KEAP1 protein binds to SQSTM1 protein]]; pyrazolanthrone inhibits the reaction [pachastrissamine analog results in increased expression of SQSTM1 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased expression of SQSTM1 protein]; pyrazolanthrone inhibits the reaction [tetrachlorobenzoquinone results in increased expression of SQSTM1 protein] pyrazolanthrone results in increased expression of SQSTM1 protein pyrazolanthrone results in decreased expression of SQSTM1 protein pyrazolanthrone inhibits the reaction [methylmercuric chloride results in increased expression of SQSTM1 protein]; pyrazolanthrone inhibits the reaction [triethylene glycol dimethacrylate results in increased expression of SQSTM1 protein] pyrazolanthrone inhibits the reaction [Colistin results in increased degradation of SQSTM1 protein] |
CTD |
PMID:24833599 PMID:25881548 PMID:27393035 PMID:27667695 PMID:28842171 PMID:33035517 PMID:33684387 PMID:34861471 PMID:35123989 More...
|
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [FGF7 protein results in increased expression of SREBF1 protein] |
CTD |
PMID:16162944 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of SREBF2 protein]; pyrazolanthrone inhibits the reaction [Quercetin results in increased metabolism of and affects the localization of SREBF2 protein] |
CTD |
PMID:22388943 PMID:33677747 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Srrt |
serrate, RNA effector molecule |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of SRRT protein] |
CTD |
PMID:23219847 |
|
NCBI chr12:19,392,578...19,406,098
Ensembl chr12:19,392,625...19,406,095
|
|
G |
St8sia3 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Tretinoin results in increased expression of ST8SIA3 mRNA] |
CTD |
PMID:17069899 |
|
NCBI chr18:57,754,349...57,760,839
Ensembl chr18:57,754,347...57,760,839
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
EXP ISO |
pyrazolanthrone inhibits the reaction [nickel sulfate results in decreased expression of STAR mRNA]; pyrazolanthrone inhibits the reaction [nickel sulfate results in decreased expression of STAR protein] pyrazolanthrone inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of STAR protein] |
CTD |
PMID:29567110 PMID:32199951 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [[Diclofenac co-treated with IFNG protein] results in increased phosphorylation of STAT1 protein]; pyrazolanthrone inhibits the reaction [Aluminum Chloride results in increased activity of STAT1 protein]; pyrazolanthrone inhibits the reaction [Aluminum Chloride results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:26609140 PMID:36154299 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions increases phosphorylation |
ISO EXP |
pyrazolanthrone inhibits the reaction [1,2,5,8-tetrahydroxy anthraquinone results in decreased phosphorylation of STAT3 protein]; pyrazolanthrone inhibits the reaction [1,4-naphthoquinone analog results in decreased phosphorylation of STAT3 protein]; pyrazolanthrone inhibits the reaction [arsenic trichloride results in increased phosphorylation of STAT3 protein]; pyrazolanthrone inhibits the reaction [bisphenol A results in increased phosphorylation of STAT3 protein]; pyrazolanthrone inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein] pyrazolanthrone inhibits the reaction [arsenic trioxide results in increased phosphorylation of and affects the localization of STAT3 protein] pyrazolanthrone results in increased phosphorylation of STAT3 protein |
CTD |
PMID:19429262 PMID:22696236 PMID:24349194 PMID:27174766 PMID:30871965 PMID:33030807 More...
|
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Gallic Acid results in increased expression of SULT1A1 protein] |
CTD |
PMID:16308312 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Syt11 |
synaptotagmin 11 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Ozone results in increased expression of SYT11 mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr 2:174,206,032...174,232,540
Ensembl chr 2:174,206,191...174,231,964
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
pyrazolanthrone promotes the reaction [GR 73632 promotes the reaction [Capsaicin results in increased secretion of TAC1 protein]] |
CTD |
PMID:18809416 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Taldo1 |
transaldolase 1 |
multiple interactions |
ISO |
pyrazolanthrone affects the reaction [TALDO1 gene mutant form promotes the reaction [Acetaminophen results in increased activity of and results in increased phosphorylation of MAPK8 protein]] |
CTD |
PMID:19436114 |
|
NCBI chr 1:196,493,634...196,503,965
Ensembl chr 1:196,493,589...196,503,974
|
|
G |
Tardbp |
TAR DNA binding protein |
multiple interactions |
ISO |
pyrazolanthrone promotes the reaction [Paraquat results in increased expression of TARDBP protein modified form] |
CTD |
PMID:22879928 |
|
NCBI chr 5:159,050,518...159,062,218
Ensembl chr 5:159,051,799...159,062,055
|
|
G |
Tat |
tyrosine aminotransferase |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Colchicine results in decreased expression of TAT mRNA] |
CTD |
PMID:15744361 |
|
NCBI chr19:37,947,153...37,957,717
Ensembl chr19:37,947,112...37,958,031
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions |
ISO |
[pyrazolanthrone co-treated with SB 203580 co-treated with U 0126] inhibits the reaction [Isothiocyanates results in increased expression of TERT mRNA] |
CTD |
PMID:23382840 |
|
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [arsenite results in increased expression of and results in increased secretion of TGFA protein] |
CTD |
PMID:36343453 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO EXP |
pyrazolanthrone inhibits the reaction [Asbestos, Serpentine results in increased secretion of TGFB1 protein]; pyrazolanthrone inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Cisplatin]]; pyrazolanthrone inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased expression of TGFB1 mRNA]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased secretion of TGFB1 protein] 6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride affects the reaction [pyrazolanthrone affects the reaction [[TGFB1 protein co-treated with TNF protein] affects the expression of PPARGC1A protein]]; pyrazolanthrone affects the reaction [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride affects the reaction [[TGFB1 protein co-treated with TNF protein] affects the expression of PPARGC1A protein]]; pyrazolanthrone affects the reaction [[TGFB1 protein co-treated with TNF protein] affects the expression of PPARGC1A protein] pyrazolanthrone inhibits the reaction [Patulin results in increased expression of TGFB1 protein] |
CTD |
PMID:16365456 PMID:21613822 PMID:25358858 PMID:31447676 PMID:34896196 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Thpo |
thrombopoietin |
multiple interactions |
ISO |
pyrazolanthrone promotes the reaction [THPO protein results in increased expression of GP1BA protein]; pyrazolanthrone promotes the reaction [THPO protein results in increased expression of ITGA2B protein]; pyrazolanthrone promotes the reaction [THPO protein results in increased expression of ITGB3 protein] |
CTD |
PMID:20523355 |
|
Ensembl chr11:80,182,820...80,188,167
|
|
G |
Thra |
thyroid hormone receptor alpha |
increases expression multiple interactions |
ISO |
pyrazolanthrone results in increased expression of THRA mRNA alternative form [Sulfasalazine co-treated with pyrazolanthrone] results in decreased expression of THRA mRNA; IL1B protein inhibits the reaction [[Sulfasalazine co-treated with pyrazolanthrone] results in decreased expression of THRA mRNA]; IL1B protein inhibits the reaction [pyrazolanthrone results in increased expression of THRA mRNA alternative form] |
CTD |
PMID:17641275 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [thymoquinone results in increased expression of TIMP1 protein] |
CTD |
PMID:27060453 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [thymoquinone results in increased expression of TIMP2 protein] |
CTD |
PMID:27060453 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
pyrazolanthrone affects the reaction [TNF protein results in increased expression of MMP9 protein]; pyrazolanthrone inhibits the reaction [[cholix toxin, Vibrio cholerae co-treated with TNF protein] results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [[ochratoxin A co-treated with Citrinin] results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [Benzo(a)pyrene results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [beta Carotene promotes the reaction [Benzo(a)pyrene results in increased secretion of TNF protein]]; pyrazolanthrone inhibits the reaction [lead acetate results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of and results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [polyhexamethyleneguanidine results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in decreased expression of HNF4A mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in decreased expression of PPARA mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in increased activity of PLAU protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of and results in increased activity of MMP9 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of CXCL8 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of CYP4F11 mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of F3 mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of PLAU protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased phosphorylation of MAPK9 protein] 6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride affects the reaction [pyrazolanthrone affects the reaction [[TGFB1 protein co-treated with TNF protein] affects the expression of PPARGC1A protein]]; pyrazolanthrone affects the reaction [6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochloride affects the reaction [[TGFB1 protein co-treated with TNF protein] affects the expression of PPARGC1A protein]]; pyrazolanthrone affects the reaction [[TGFB1 protein co-treated with TNF protein] affects the expression of PPARGC1A protein]; pyrazolanthrone inhibits the reaction [[Cisplatin co-treated with TNF protein] results in increased expression of XAF1 mRNA]; pyrazolanthrone inhibits the reaction [[Polysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of TNF protein]; pyrazolanthrone inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [bisphenol A results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [Cisplatin inhibits the reaction [TNF protein affects the localization of RELA protein]]; pyrazolanthrone inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; pyrazolanthrone inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [Ozone results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [perfluorooctane sulfonic acid results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [TNF protein promotes the reaction [diethyl maleate results in increased phosphorylation of JUN protein]]; pyrazolanthrone inhibits the reaction [TNF protein results in decreased expression of ADIPOQ mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased phosphorylation of JUN protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased susceptibility to Acetaminophen]; pyrazolanthrone inhibits the reaction [TNF protein results in increased susceptibility to Chlorpromazine]; pyrazolanthrone inhibits the reaction [trovafloxacin promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; pyrazolanthrone inhibits the reaction [trovafloxacin results in increased expression of TNF mRNA]; pyrazolanthrone promotes the reaction [[Cisplatin co-treated with TNF protein] results in increased phosphorylation of JUN protein] pyrazolanthrone inhibits the reaction [2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]]; pyrazolanthrone inhibits the reaction [7-Ala-angiotensin (1-7) inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]]; pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of TNF protein]; pyrazolanthrone inhibits the reaction [Acrylamide results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [lead acetate results in increased expression of TNF protein]; pyrazolanthrone inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]]; pyrazolanthrone inhibits the reaction [Palmitic Acid results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of and results in increased secretion of TNF protein]; pyrazolanthrone inhibits the reaction [Paraquat results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [Particulate Matter results in increased expression of TNF mRNA]; pyrazolanthrone inhibits the reaction [TNF protein affects the localization of RELA protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of and results in increased secretion of MMP9 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of OPTN protein] |
CTD |
PMID:12774022 PMID:14644621 PMID:15302094 PMID:15322261 PMID:16271621 PMID:16488514 PMID:17185352 PMID:17460151 PMID:17464197 PMID:18577375 PMID:19812349 PMID:19874453 PMID:19883121 PMID:20118172 PMID:20166895 PMID:20371967 PMID:20712904 PMID:20932985 PMID:21447443 PMID:22705379 PMID:22728154 PMID:22926441 PMID:23103562 PMID:23268108 PMID:23535185 PMID:23774252 PMID:23831309 PMID:24525298 PMID:25047101 PMID:25677194 PMID:26691871 PMID:27302421 PMID:28087840 PMID:28474156 PMID:28483571 PMID:28776281 PMID:29426002 PMID:29673704 PMID:29906494 PMID:30078834 PMID:30259999 PMID:31199065 PMID:31447676 PMID:38104653 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Alprostadil results in increased secretion of TNFRSF11B protein]; pyrazolanthrone inhibits the reaction [Dinoprost results in increased expression of and results in increased secretion of TNFRSF11B protein]; pyrazolanthrone inhibits the reaction [Dinoprostone results in increased secretion of TNFRSF11B protein]; pyrazolanthrone inhibits the reaction [FGF2 protein results in increased secretion of TNFRSF11B protein]; pyrazolanthrone inhibits the reaction [Prostaglandin D2 results in increased secretion of TNFRSF11B protein] |
CTD |
PMID:24333336 PMID:24813642 PMID:25234201 PMID:25290095 PMID:25677506 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of TNFSF10 mRNA]; pyrazolanthrone results in increased susceptibility to [[TNFSF10 protein co-treated with kahweol acetate] results in increased cleavage of PARP1 protein] |
CTD |
PMID:17545621 PMID:20403343 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
[crocin co-treated with pyrazolanthrone co-treated with TNFSF11 protein] results in decreased expression of OSTM1 mRNA; [TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of AKT2 mRNA; [TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of MAPK3 mRNA; [TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of OSTM1 mRNA; [TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of TRAF6 mRNA; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of AKT2 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of MAPK3 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of OSTM1 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of TRAF6 mRNA]; crocin promotes the reaction [pyrazolanthrone inhibits the reaction [TNFSF11 protein results in increased activity of ACP5 protein]]; pyrazolanthrone inhibits the reaction [TNFSF11 protein results in increased activity of ACP5 protein] |
CTD |
PMID:30580027 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnni2 |
troponin I2, fast skeletal type |
multiple interactions |
ISO |
pyrazolanthrone promotes the reaction [Ozone results in increased expression of TNNI2 mRNA] |
CTD |
PMID:17460151 |
|
NCBI chr 1:197,595,012...197,597,554
Ensembl chr 1:197,594,813...197,597,560
|
|
G |
Top1 |
DNA topoisomerase I |
multiple interactions |
ISO |
[pyrazolanthrone results in decreased phosphorylation of JUN protein] inhibits the reaction [JUN protein binds to TOP1 protein] |
CTD |
PMID:15923621 |
|
NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions decreases expression increases expression increases phosphorylation |
ISO EXP |
[sodium arsenite co-treated with pyrazolanthrone] promotes the reaction [HSPA9 protein binds to TP53 protein modified form]; MYC affects the reaction [pyrazolanthrone results in increased expression of TP53 protein]; pyrazolanthrone inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein modified form]; pyrazolanthrone inhibits the reaction [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone analog results in increased expression of TP53 protein]; pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased expression of TP53 protein]; pyrazolanthrone inhibits the reaction [Capsaicin results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein]; pyrazolanthrone inhibits the reaction [Cisplatin results in increased stability of TP53 protein]; pyrazolanthrone inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein]; pyrazolanthrone inhibits the reaction [Pyrogallol results in increased expression of TP53 protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased phosphorylation of TP53 protein]; pyrazolanthrone inhibits the reaction [tributyltin results in increased expression of TP53 protein] pyrazolanthrone results in decreased expression of TP53 protein pyrazolanthrone results in increased expression of TP53 protein; pyrazolanthrone results in increased expression of TP53 protein modified form pyrazolanthrone results in increased phosphorylation of TP53 protein pyrazolanthrone promotes the reaction [TRP53 gene mutant form results in decreased susceptibility to sodium arsenite] pyrazolanthrone inhibits the reaction [Colistin results in increased expression of TP53 protein] |
CTD |
PMID:15034932 PMID:16046226 PMID:16061660 PMID:16166651 PMID:16450001 PMID:17292493 PMID:20191265 PMID:22706169 PMID:25305377 PMID:25939952 PMID:26630137 PMID:28842171 PMID:31734849 PMID:32238696 PMID:36319700 More...
|
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of TRAF6 mRNA; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of TRAF6 mRNA] |
CTD |
PMID:30580027 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Trhr |
thyrotropin releasing hormone receptor |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [2,4,5,2',4',5'-hexachlorobiphenyl results in decreased expression of TRHR protein] |
CTD |
PMID:22889935 |
|
NCBI chr 7:75,348,672...75,393,310
Ensembl chr 7:75,348,672...75,393,309
|
|
G |
Twist1 |
twist family bHLH transcription factor 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [thymoquinone results in decreased expression of TWIST1 protein] |
CTD |
PMID:27060453 |
|
NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653
|
|
G |
Uba7 |
ubiquitin-like modifier activating enzyme 7 |
decreases expression |
ISO |
pyrazolanthrone results in decreased expression of UBA7 protein |
CTD |
PMID:25649257 |
|
NCBI chr 8:108,665,289...108,674,097
Ensembl chr 8:108,665,292...108,674,099
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [chrysin results in increased expression of UGT1A1 mRNA] |
CTD |
PMID:17256720 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] pyrazolanthrone inhibits the reaction [Cadmium results in increased expression of VCAM1 mRNA]; pyrazolanthrone inhibits the reaction [Cadmium results in increased expression of VCAM1 protein]; pyrazolanthrone inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:16271621 PMID:19609071 PMID:28483571 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vdr |
vitamin D receptor |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Estradiol results in increased expression of VDR protein] |
CTD |
PMID:15930183 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [andrographolide results in decreased expression of VEGFA mRNA]; pyrazolanthrone inhibits the reaction [andrographolide results in decreased expression of VEGFA protein]; pyrazolanthrone inhibits the reaction [hydroxyethyl methacrylate results in decreased secretion of VEGFA protein]; pyrazolanthrone inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]; pyrazolanthrone inhibits the reaction [VEGFA protein results in increased expression of PTGS2 mRNA]; pyrazolanthrone inhibits the reaction [VEGFA protein results in increased expression of PTGS2 protein] |
CTD |
PMID:18596194 PMID:19176594 PMID:23968725 PMID:28651835 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM mRNA]; pyrazolanthrone inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]; pyrazolanthrone inhibits the reaction [thymoquinone results in decreased expression of VIM protein] |
CTD |
PMID:27060453 PMID:33396024 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Xaf1 |
XIAP associated factor 1 |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [[Cisplatin co-treated with TNF protein] results in increased expression of XAF1 mRNA] |
CTD |
PMID:23103562 |
|
NCBI chr10:56,917,378...56,929,791
Ensembl chr10:56,917,121...56,929,770
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [trimethyltin chloride results in decreased expression of XIAP protein] |
CTD |
PMID:23423712 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Ywhaz |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta |
multiple interactions |
ISO |
pyrazolanthrone inhibits the reaction [Methylmercury Compounds inhibits the reaction [BAX protein binds to YWHAZ protein]] |
CTD |
PMID:34999165 |
|
NCBI chr 7:67,941,353...67,963,651
Ensembl chr 7:67,940,017...67,963,668
|
|
G |
Yy1 |
YY1 transcription factor |
multiple interactions |
EXP |
[pyrazolanthrone co-treated with cypermethrin] results in decreased expression of YY1 protein |
CTD |
PMID:34794910 |
|
NCBI chr 6:127,706,739...127,736,499
Ensembl chr 6:127,707,596...127,732,747
|
|
G |
Zc3h12a |
zinc finger CCCH type containing 12A |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Silicon Dioxide results in increased expression of ZC3H12A protein] |
CTD |
PMID:26865670 |
|
NCBI chr 5:137,376,562...137,385,351
Ensembl chr 5:137,376,564...137,385,351
|
|